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ABSTRACT
Recovery from central nervous system (CNS) injuries is hindered by a lack of
spontaneous regeneration. In injuries such as stroke and traumatic brain injury, loss of
viable tissue can lead to cavitation as necrotic debris is cleared. Using a rat model of
penetrating brain injury, this thesis investigated the use of collagen biomaterials to fill a
cavitary brain defect and deliver therapeutic agents.
Characterization of the untreated injury revealed lesion volume expansion of 29%
between weeks 1 and 5 post-injury. The cavity occupied parts of the striatum and cortex
in the left hemisphere, and was surrounded by glial scarring.
Implantation of a collagen scaffold one week after injury resulted in a modest
cellular infiltrate four weeks later consisting of macrophages, astrocytes, and endothelial
cells. The scaffold was able to fill the cavity and provide a substrate for cellular
migration into the defect.
Incorporation of a Nogo receptor molecule aimed at binding inhibitory myelin
proteins did not appear to promote axonal regeneration, but resulted in increased
infiltration of macrophages and endothelial cells. The increased vascularization observed
within the scaffolds represents a modified environment that might be more suitable for
regenerative therapies.
A scaffold was also used to investigate the delivery of neural progenitor cells one
week after injury. After four weeks, viable implanted cells were found to have
differentiated into astrocytes, oligodendrocytes, endothelial cells, neurons, and possibly
macrophages/microglia.
These results demonstrate the potential utility of combinatorial therapies
involving collagen biomaterials, myelin protein antagonists, and neural progenitors for
treatment of CNS injuries.
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Chapter 1: Introduction and Background
1.1 General Introduction
Injuries and diseases of the central nervous system (CNS) are particularly
devastating due to the lack of spontaneous tissue regeneration. Stroke, neurodegenerative
disease, spinal cord injury, and traumatic brain injuries collectively present a major health
care challenge for both the civilian and military populations. A more extensive
understanding of the cellular and environmental regenerative limitations involved in CNS
lesions will be necessary for the development of effective treatments. While considerable
challenges remain, many elements of the physiological injury response in the CNS are
now known. This improved body of knowledge has made clear that the complexity of
CNS lesions is likely to require combinatorial therapies targeting several distinct
components of the pathologies. In general, the factors preventing regeneration can be
divided into intrinsic cellular limitations and extrinsic elements of the injury
environments [1, 2]. Devising comprehensive methods to simultaneously and adequately
address these factors will be a prerequisite for ultimately achieving more satisfactory
clinical outcomes.
This work aims to investigate several therapeutic agents with potential utility in
treatment of CNS lesions. The starting point for the proposed work is a collagen scaffold
that can be implanted into a damaged brain. This biomaterial provides a foundation for
subsequent studies of combinatorial therapies involving delivery of a therapeutic protein
or a population of neural progenitor cells.
This chapter begins with an overview of some of the major obstacles that must be
overcome in the process of developing CNS treatments. This is followed by descriptions
of common CNS injuries and diseases, as well as a summary of various research tools
used in CNS tissue engineering. The chapter concludes with an outline of the
experiments included in this thesis.
1.2 Intrinsic Factors Limiting Regeneration
Intrinsic cellular limitations refer to the insufficient capacity of existing cells to
proliferate, grow, and potentially replace damaged or dead cells [1]. A major obstacle
lies in the fact that mature neurons do not proliferate, and therefore are unable to
repopulate a region of the brain or spinal cord lost to disease or injury. Similarly, mature
neurons that undergo damage have a greatly limited ability to extend axons relative to
developing cells. One reason for this is the decreased expression of genes such as GAP-
43 [3] that regulate the growth of axons and establishment of synapses. Further, various
neuronal subtypes differ substantially in their intrinsic axonal growth capability and their
response to exogenous environmental factors [4]. While the existence and multipotency
of endogenous neural progenitors in the brain and spinal cord have been demonstrated,
they appear to be insufficient for robust CNS repair in their native form and number.
1.3 Extrinsic Factors Limiting Regeneration
Although the axonal growth capacity of mature neurons is not as robust as during
development, a significant degree of regeneration is theoretically still be possible. This
potential for regeneration is defeated largely by inhibitory factors in the CNS injury
environment. It was demonstrated, for example, that neurons from the CNS can extend
long distances through a peripheral nerve graft [5]. Identifying and targeting the
inhibitory extrinsic elements in the CNS will be necessary for achieving regeneration.
1.3.1 Myelin Proteins
It was discovered early on that oligodendrocyte myelin is inhibitory for growing
axons, causing acute growth cone collapse [6]. 3 particular myelin proteins were
eventually identified and characterized as major axon growth inhibitors: Reticulon 4
(Nogo) [7], Oligodendrocyte Myelin Glycoprotein (OMgp) [8], and Myelin Associated
Glycoprotein (MAG) [9]. Interestingly, it was found that they bind a common receptor,
known as Nogo Receptor (NgR) [8, 10-12]. NgR is a 473 amino acid
glycosylphosphatidylinositol-anchored (GPI-anchored) protein, which includes 8 leucine-
rich-repeat domains that are involved in ligand-binding[13, 14]. Although NgR is a
receptor for several signaling molecules, it lacks an intracellular domain and must rely on
co-receptors such as P75 [15, 16], LINGO-I [17], Gtlb, and TROY [18, 19] for
intracellular signaling [20]. The intracellular signaling cascade following binding of the
NgR complex leads to collapse of axonal growth cones by activation of cytoskeletal
regulators such as rhoA GTPase and rho kinase (ROCK) [21, 22]. The NgR pathway has
been the subject of much research over the last decade. While many promising results
have been obtained, it has become clear that additional approaches will be necessary
going forward. Recently, the paired immunoglobulin-like receptor B (PirB) in mice was
also found to bind the 3 myelin proteins and act as an inhibitor of axonal regeneration
[23]. This discovery has helped to explain some confounding results previously obtained
while studying NgR, particularly the result that NgR knockout mice show only
moderately enhanced regeneration after CNS injury [24]. This and other work has
demonstrated that blocking the effects of myelin proteins or their downstream targets will
be an important part of a comprehensive treatment plan for certain CNS lesions.
Recent findings have suggested that the same myelin proteins involved in growth
cone collapse may also have effects on neural progenitor cells (NPCs). The use of NPCs
has been hindered in part by a lack of control over differentiation after implantation, with
some results suggesting a tendency to either remain undifferentiated or to take on an
astroglial phenotype. Similar effects were demonstrated in vitro when NPCs expressing
NgR were exposed to Nogo or its active inhibitory fragment [25-27]. It is possible then
that myelin proteins may play a role in limiting the efficacy of both implanted and
endogenous NPCs after injury.
1.3.2 Glial Scar
Another major factor inhibiting axonal regeneration is the presence of a glial scar
[28]. While scar tissue in peripheral organs such as skin and peripheral nerve is
characterized by fibrous collagen deposition and wound contraction, scar in the CNS is
markedly different. Following a CNS injury, resident astrocytes respond to
environmental cues by proliferating and taking on a ramified phenotype known as an
"activated" astrocyte. The astrocytes, along with microglia, migrate to the site of the
injury and surround it with a cellular barrier [29]. Additionally, they deposit extracellular
matrix molecules consisting of axon-inhibitory chondroitin sulfate proteoglycans [30].
Until recently, the precise mechanism by which CSPGs inhibit regeneration was
unknown. While it had been suggested that the mechanism involved activation of protein
kinase C and rho GTPase, evidence for binding to a particular receptor was lacking [31].
It was also observed that disrupting epidermal growth factor (EGFR) signaling blocked
some of the inhibitory effects, EGFR was not found to directly bind CSPGs [31]. It was,
however, recently discovered that a transmembrane protein tyrosine phophatase (PTPG) is
a receptor for CSPGs, and that disruption of PTPG after spinal cord injury resulted in
enhanced regeneration [32]. As this area of research continues, it is likely that novel
therapies will be available to better target the inhibitory nature of the glial scar.
To date, many therapeutic approaches have focused on disrupting either the
formation of the glial scar, or the scar itself after the acute injury response has subsided.
Approaches of interest include blocking elements of the inflammatory cascade [28], using
biomaterials to prevent formation of the cellular barrier [33], and enzymatic degradation
of the inhibitory extracellular matrix (ECM) molecules using chondroitinase [31, 34].
While eliminating elements of the glial scar will likely be necessary in developing
treatment options, it has been suggested that the timing of such action is of critical
importance. Studies have demonstrated positive effects of the reactive astrocytes in early
stages following an acute insult [35, 36], and thus it may be essential to allow initial scar
formation without inhibition to avoid further injury.
1.3.3 Inhibitory Axon Guidance Molecules
In addition to the myelin proteins that act through NgR, there exist other
molecules that can exert inhibitory actions on neurons. While axon guidance molecules
play a crucial role in proper development of the CNS, a subset of them that possess axon-
repulsive characteristics are prevalent in lesion sites and act to inhibit regeneration.
Netrin- 1, for example, continues to be expressed by mature neurons, oligodendrocytes,
and Schwann cells. Molecules such as Semaphorins, ephrins and various slits have also
been found in the glial scar and CNS myelin. Repulsive guidance molecule A (RGMa) is
expressed in the adult spinal cord and appears to play a role in preventing recovery after
injury. Neutralizing axon guidance molecules may prove to be an important component
of future therapies [37].
1.3.4 Lack of Neurotrophic Factors
Aside from active inhibitors, it may also be that the lesion environment is lacking
the trophic factors necessary for neuronal survival and axonal outgrowth. A variety of
molecules have been identified and characterized for their ability to promote neuronal
survival and growth.
The neurotrophins make up one such class of molecules consisting of nerve
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3),
and neurotrophin 4/5 (NT-4/5). Neurotrophins have a major role in promoting neuronal
survival, but also act to regulate axon growth, synapse formation, dendrite formation, cell
migration, and proliferation. Neurotrophins are known to act through specific tyrosine
kinase receptors, with NGF binding to tyrosine kinase receptor A (TrkA), BDNF and NT-
4/5 binding to TrkB, and NT-3 to TrkC. Additionally, all neurotrophins can bind to the
receptor p7 5NTR hough with lower affinity. The response to individual neurotrophins
does, however, vary substantially between neuronal subtypes [38].
Glial cell line-derived neurotrophic factor (GDNF), along with the molecules
neurturin, artemin, and persephin compose a distinct group of neurotrophic factors.
GDNF acts through a receptor complex involving GNDF family receptor and rearranged
during transfection (RET) Trk, with subsequent effects of promoting neuronal survival
and axonal regeneration. GDNF has demonstrated particular benefit for survival of
motoneurons and dopaminergic neurons, making it a therapeutic candidate for
amyotrophic lateral scleroris and Parkinson's disease [38].
Members of the fibroblast growth factor (FGF) family have also been shown to
enhance neuronal survival and neurite outgrowth. FGFs can have several distinct effects,
such as maintaining calcium homeostasis, regulating enzymes involved in neutralizing
reactive oxygen species, and stimulating anti-apoptotic pathways. Further, the FGF-2
(also known as basic FGF) is a mitogen that appears to be important in preventing
differentiation of neural (and other) progenitors and maintaining their multipotency [38].
Ciliary neurotrophic factor (CNTF) is another molecule with demonstrated
neuroprotective effects [38].
1.4 Injuries to the Central Nervous System
1.4.1 Traumatic Brain Injury: Non-penetrating
Traumatic brain injury (TBI) presents a significant cause of morbidity and
mortality in military conflicts and also in the civilian sector. Roadside bombs and
improvised explosive devices in Iraq and Afghanistan have made TBI an increasingly
common problem, with few good treatment options. The severity of TBI can range from
mild injuries imperceptible by standard imaging modalities, to penetrating injuries
causing extensive hemorrhage and loss of brain tissue. From an interventional
standpoint, closed head injuries present a difficulty in administering treatment. While
considerable work remains in understanding the pathophysiology of such injuries, there is
a challenge in determining whether a potential therapy should be administered directly
via surgery, or peripherally. Peripheral administration requires that the agent can cross
the blood-brain barrier, a topic of considerable pharmacological research. Surgery, on
the other hand, presents obvious risks and complications that may outweigh the potential
benefit of the therapy.
1.4.2 Traumatic Brain Injury: Penetrating
Penetrating brain injury may be more amenable to therapy administered
surgically, due to the fact that surgical intervention is often acutely necessary after the
injury. While PBI has unique characteristics not found in closed head injuries, there are
similarities particularly in the secondary injury response that may be applicable to other
TBI scenarios, as well as ischemic or hemorrhagic insults. By studying potential
implantable therapeutics in a model of PBI, one can begin to assess whether such options
would be of sufficient benefit to warrant surgical intervention in other CNS lesions.
When relatively high velocity objects enter the brain in a PBI, they create a
complex wound resulting largely from radial dissipation of the projectile's kinetic energy.
Tissue surrounding the projectile track is rapidly compressed, leading to the formation of
a temporary cavity larger than the actual projectile. The projectile injury track is thus
surrounded by a significantly larger amount of injured tissue as a result of the temporary
cavity [39]. While the tissue associated with the permanent injury track of the projectile
has generally been destroyed, the surrounding peri-lesional area may potentially be
salvageable if an appropriate therapy were applied soon enough [40].
The initial mechanical insult of a penetrating brain injury causes disruption of
membranes associated with blood vessels, cell bodies, and axons. A large degree of
hemorrhage rapidly ensues and intracellular contents of damaged neurons and glial cells
are released. The loss of blood supply associated with damaged vessels causes metabolic
and ischemic stress to areas of surrounding tissue, while the release of intracellular
contents produces an extracellular ionic imbalance (Ca2+, Na*, K*), contributing to
diffuse axonal injury. Breakdown of axons leads to release of myelin components that
act to inhibit potential regeneration [41].
Release of cytokines, as well as breakdown of the blood-brain-barrier, causes a
large inflammatory response consisting of both resident microglia and peripheral
leukocytes. Reactive astrocytes proliferate and surround the injury site, creating a glial
scar both with their cell bodies and production of axon-inhibitory extracellular matrix
(ECM) molecules. With time, a delayed degeneration of axons and neuronal cell bodies
remote from the lesion occurs, possibly as a result of lost synaptic targets and retrograde
degeneration from sites of axonal injury. It is also thought that myelin proteins may play
a role in remote degeneration in the thalamus. Electrophysiological abnormalities ensue
and functional deficits become apparent depending on the location and extent of injury.
At the injury site, debris and dead cells are eventually cleared and a permanent cavity
remains [42, 43]. Bone and metal fragments remaining in the brain pose a serious risk for
infection and seizure.
It has also been suggested that the pressure wave during PBI damages axons that
connect to brainstem respiratory centers, leading in some cases to apnea and subsequent
death [44].
Treatment options are limited in PBL. Surgical intervention typically involves
debridement of necrotic tissue and removal of accessible bone and metal fragments [45].
In many cases, risk of damaging functional brain tissue precludes the removal of all
fragments. In these cases, there exists no broad consensus on how aggressively to pursue
the removal of embedded fragments [46]. However, recent advances in image-guided
surgery present possibilities for improved removal techniques to safely eliminate as much
foreign matter as possible from the brain [47]. With better imaging, the surgeons can
choose less destructive paths for accessing fragments and potentially minimize damage to
viable tissue.
Given the temporal limitations in getting patients, particularly in military settings,
to surgery, it is a major challenge to devise an appropriate treatment for the acute injury
phase. Although significantly mitigating the primary injury process may not be currently
feasible, there may be a great deal that can be done to limit secondary tissue damage.
While it has been shown that degeneration of both white and gray matter persists long
after traumatic brain injury [48], there are currently no effective pharmacological agents
or surgical therapies to significantly disrupt this process. Implantation of a biomaterial or
other drug-delivery agent during the time of surgery may allow damaged or ischemic
neural cells to survive. Further, promoting axonal regeneration may prevent the loss of
additional neurons by allowing the reestablishment of synapses disrupted by the lesion.
1.4.3 Ischemic Stroke
Ischemic stroke is caused by an interruption of blood supply to the brain, often as
a result of thrombosis or embolism. Death of neurons occurs rapidly in the absence of
oxygen, leading to permanent neurological damage depending on the duration before
reperfusion can be established. While a particularly region of the brain may be damaged
beyond repair, there is often a region of ischemic tissue referred to as a penumbra that
may be viable with appropriate intervention. For this reason, it is imperative that
treatment is sought as soon as possible after recognition of the event. The penumbra and
areas more remote from the region are susceptible to further injury and neuronal
degeneration [49]. Neuroprotective agents that may improve the amount of spared tissue
and decrease remote degeneration are thus a topic of intense research. The complexity of
this goal is emphasized by the fact that numerous clinical trials to date have not shown
benefits for neuroprotective drugs [50].
The design and application of such therapies depends on knowledge of how
ischemia leads to neuronal cell death and degeneration. The ischemic cascade begins
with reduction of ATP production due to loss of the oxygen supply. Without adequate
energy supplies, ATP-dependent ion pumps fail, disrupting the regular ionic balance and
cell potential. Influx of calcium leads to release of glutamate, which excites other cells
and results in an even greater calcium influx and eventually more glutamate release. The
result of this uncontrolled positive feedback is excitotoxic damage from production of
calcium dependent enzymes. Breakdown of the cell membrane leads to influx of
extracellular ions and molecules, and also to release of intracellular contents that further
alter the extracellular environment [51].
Application of a biomaterial supplemented with neuroprotective agents and
perhaps neural progenitor cells may have the potential to reduce secondary injury and
promote regeneration.
1.4.4 Hemorrhagic Stroke
Many of the pathophysiological effects are similar in ischemic and hemorrhagic
stroke, but hemorrhagic events tend to be significantly more severe. In addition to the
potential for dangerous rises in intracranial pressure due to hematomas, hemoglobin in
the blood is cytotoxic and may cause increased neuronal death [52]. Delivery of
neuroprotective therapeutics and agents to neutralize hemoglobin toxicity may help
clinical outcome.
1.4.5 Spinal Cord Injury
Spinal cord injuries affect several million people worldwide, with a wide range of
severities including debilitating conditions like quadriplegia and diaphragm paralysis.
Such injuries can result from contusion, compression, and partial or complete severing of
the cord [53]. Pathophysiological events include the death of neuronal cell bodies at the
injury site, remote degeneration of neurons whose axons have been severed, myelin
breakdown, severe inflammation, and formation of a glial scar [54]. As with injuries to
the brain, combinatorial therapies involving biomaterials, cells, growth factors, and
antagonists to inhibitory molecules offer significant promise for restoring function.
1.5 Neurodegenerative Diseases
1.5.1 Parkinson's
Parkinson's disease is characterized by loss of dopaminergic neurons of the substantia
nigra region of the basal ganglia. These neurons play a direct role in regulation of the
striatum as part of the direct and indirect basal ganglia pathways. These pathways
contribute to control of cortical excitation through the thalamus, modulating voluntary
movement. Pharmacological therapy currently involves administration of L-Dopa, a
dopamine precursor that can cross the blood-brain barrier before being metabolized to
dopamine. While this helps to control symptoms, it does not stop the progressive loss of
the dopaminergic neurons. Alternative therapies are aimed at alterations of the basal
ganglia pathways by surgical lesions or an implantable deep brain stimulation device.
Cell replacement is a promising therapeutic approach for Parkinson's, as significant
progress has been made in directing stem/progenitor cells to differentiate into
dopaminergic neurons [55]. Developing a viable dopaminergic cell-scaffold construct for
implantation into the substantia nigra could be a potentially beneficial therapeutic
strategy.
1.5.2 Alzheimer's
Alzheimer's disease is a common form of dementia that is characterized by the
loss of cortical neurons and degeneration in various other brain regions. In addition to
marked cortical atrophy, histological analysis of Alzheimer's brains shows accumulation
of amyloid plaques and neurofibrillary tangles. Plaques consist of beta amyloid peptides
that improperly accumulate due to abnormal folding. Research into the processing and
function of amyloid precursor protein (APP) will aid in the understanding of how
amyloid plaques form. Therapeutic approaches are aimed at reducing beta amyloid
accumulation, though a long-term goal may also be to regenerate lost cortical neurons.
Interestingly, it has been found that APP associates physically with the Nogo receptor
[56].
1.5.3 Huntington's
Huntington's disease is an autosomal dominant genetic neurological disease that
results in an abnormal movement disorder (chorea) and decline in cognitive ability. The
disease is caused by a mutation of the Huntingtin gene such that it contains an
abnormally large number of trinucleotide repeats [57]. The resulting mutant protein
accelerates degeneration of certain subpopulations of neurons in the striatum, frontal
cortex, and temporal cortex. Astrogliosis is apparently also increased. While gene
therapy may present the best hope for a comprehensive cure, neuroprotection or
regeneration of some affected neuronal populations may be a more feasible goal in the
shorter term.
1.5.4 Amyotrophic Lateral Sclerosis (ALS)
ALS, also called Lou Gehrig's disease, is characterized by the progressive
degeneration of cortical motoneurons. Early symptoms consist of muscle weakness or
speech difficulties, but progress eventually to major problems with limb movement and
severe muscle atrophy. While the cause is unknown in most cases, a small subset of
patients have a genetic form of the disease correlated with a mutation in the superoxide
dismutase (SOD1) gene [58]. Potential therapies are aimed at preventing motoneuron
degeneration by controlling glutamate release and associated possible excitotoxic effects.
Novel neuroprotective agents combined with cell replacement therapy may present
effective future strategies.
1.5.5 Multiple Sclerosis
Multiple scleroris (MS) is an autoimmune disease that results in demyelinatin of
white matter in the CNS. Demylinated axons have poor conduction capabilities, and as a
result virtually any neurological symptom may be present. While some degree of
remyelination takes place, particularly in early stages of the diseases, the disease affects
oligodendrocytes to a degree that they cannot adequately keep up with the loss of myelin.
Therapeutic approaches have included the use of anti-inflammatory medications and
immunosuppressants. Cell therapy to promote remyelination is an area of significant
research for developing a potential future treatment [59].
1.5.6 Frontotemporal Dementia (FTD)
FTD is a dementia characterized by degeneration of neurons in the frontal and sometimes
temporal lobe of the brain [60]. Symptoms of the disease can include lethargy and
apathy, or alternatively disinhibition resulting in inappropriate social behavior. While
there is no known common cause, some cases appear to be genetic. Therapeutic options
are currently extremely limited. Neuroprotective agents or cell replacement may in the
future be able to prevent progression of the disease if applied in the early stages.
1.6 Central Nervous System Tissue Engineering
Regeneration of the Central Nervous System is extraordinarily difficult relative to
other tissues due its enormous complexity and the abundance of inhibitory factors. Given
the variation between regions of the brain and the spinal cord, there is unlikely to be a
single therapeutic approach for all problems. To replace a neuronal population with cells
of the same subtype and guide them to reestablish connections similar to those lost would
be a monumental feat.
1.6.1 Goals in the Field
CNS tissue engineering strategies currently are not necessarily aimed at trying to
produce tissue indistinguishable from that which was initially lost, though this remains a
long-term goal. At the present time, one can broadly categorize the desired outcomes as
cellular replacement, axonal regeneration, and collateral sprouting.
Cellular replacement in some cases is aimed at replacing a particular population
of lost neurons or glial cells, depending on the injury or disease. An example would be
potential therapy for Parkinson's disease. The affected neuronal subtype is known, and
theoretically it would be appropriate to simply replace the lost dopaminergic neurons
with new ones that will survive, make appropriate synapses, and carry out the desired
function. While this approach does not claim to be addressing the underlying cause of
the pathology, the goal of restoring function may still be possible. If the clinical outcome
is as desired, it becomes less important that the histological appearance of the
implantation site be exactly as in a healthy brain. Increases or decreases in cell density,
proportion of neurons relative to glia, pattern of vascularity, and volume proportion of
extracellular matrix may deviate significantly from normal yet still result in an acceptable
outcome.
Cell replacement may also be applied in scenarios where a mixed population of
cells is lost, such as in a penetrating brain injury. The challenge in this case is greater, as
cells with varying and potentially unknown functions are likely lost. The use of
stem/progenitor cells in this case offers the promise of restoring lost function if the cells
can be induced to replace those which were lost. This represents a major challenge in the
field at this time. It has been demonstrated that exogenous cells can survive and integrate
when implanted into the brain, but it is difficult to assess exactly how they are
functioning and what they are doing to improve outcome.
Promoting axonal regeneration is a more straight forward task, but remains a
challenge. In this approach, one aims to neutralize the inhibitory factors in the lesion
environment and/or enhance the growth state of neurons whose axons have been
damaged. In doing so, neurons may regain some degree of functionality as they
reestablish synapses ideally in the region near the lesion. This may prevent or limit
remote neuronal degeneration that has been noted in traumatic brain injuries and strokes.
Induction of collateral sprouting aims to promote structural plasticity of regions
that have been spared from the lesion. Rather than replacing cell bodies, it is instead
desired to compensate for those lost with the existing neurons. Similar to axonal
regeneration, blocking inhibitory factors and stimulating the growth capacity of neurons
are promising strategies.
1.6.2 Research Tools and Methods: Biomaterials
Central to the field of regenerative medicine is the use of matrices or scaffolds to
promote tissue growth. Such scaffolds can generally serve as ECM analogs for cell
attachment, migration, and contraction blocking, as well as delivery vehicles for
therapeutics such as cells, nucleic acids, proteins, and anti-inflammatory drugs. Modes of
incorporation for therapeutics can range from simple soaking like a sponge, to use of
engineered nanoparticles, to covalent bonds formed by cross-linking chemistry. Many
materials, both natural and synthetic, have been used for CNS tissue engineering [61].
Synthetic materials provide a great deal of control over the scaffold composition,
degradation rate, and mechanical behavior. Poly (ethylene glycol), Poly (ethylene-co-
vinylacetate), Poly (glycolic acid), Poly (lactic acid), Poly (lactic-co-glycolic acid), poly
(2-hydroxyethyl methacrylate), poly (2-hydroxyethyl methacrylate-co-methyl
methacrylate), and Polypyrrole are among the common synthetic materials used. These
materials have widely varying properties with respect to protein adsorption, cell
adhesion, degradability, degradation rate, mechanical stiffness, pH, and conductivity.
Natural materials are less easily modified, but have advantages such as containing
sites for cell adhesion and potentially mimicking native extracellular matrix in
composition and material properties. Common materials include agarose, chitosan,
methylcellulose, nitrocellulose, collagen, dextran, fibrin, fibronectin, laminin, and
hyaluronic acid.
1.6.3 Research Tools and Methods: Neural Stem/Progenitor Cells
While embryonic stem cells still represent exciting and profound possibilities for
regenerative medicine, the discovery of neural stem/progenitor cells in the adult brain has
spurred a tremendous amount of research. Adult neurogenesis has been confirmed to
occur in two regions of the brain: the subventricular zone (SVZ) and the subgranular
zone (SGZ) of the dentate gyrus (in the hippocampus). Cells from the SVZ travel along
the rostral migratory stream to the olfactory bulb where they become granule neurons and
periglomerular neurons. Cells from the SGZ migrate into the granule layer of the dentate
gyrus, becoming granule neurons. Both cell types can be harvested and expanded in
culture containing FGF-2. Culturing can be done either in monolayer or as neurospheres,
with monolayer culture typically requiring coating the culture flasks with laminin to
promote adhesion. SVZ and SGZ progenitors have been used in various applications and
shown to differentiate into various cell types. It appears that while they are indeed
multipotent progenitors that can become neurons, astrocytes, and oligodendrocytes, they
may not be able to differentiate into all neuronal subtypes. Additionally, their
differentiation has been shown to be highly regulated by the specific environment into
which they are implanted. For example, when SGZ cells were implanted into the
neonatal retina, they expressed neuronal and astrocytic markers while taking on
morphologies of Muller, amacrine, bipolar, horizontal, and photoreceptor cells. In the
healthy adult retina, however, the cells did not attain morphologies of normal retinal cells
[62].
Although neurogenesis appears to only occur in the SVZ and SGZ, neural
progenitors have been found elsewhere in the cortex, substantia nigra, and spinal cord.
Stimulating these existing progenitors to proliferate and differentiate in large numbers is
an active area of research.
1.6.4 Research Tools and Methods: Neurotrophic Factors
Neurotrophic factors, such as NGF, BDNF, NT-3, and GDNF have been used to
promote neuronal survival, neurite outgrowth, and axonal regeneration. While the
number of studies is extensive, an important emphasis on neurotrophic factor synergy has
developed. For example, it has been shown that combinatorial therapy with FGF-2, NT-
3, and BDNF improved the degree of retinal ganglion cell regeneration by an amount
larger than the sum of each individually [63]. Similarly, the combination of NT-3 and
BDNF proves more effective than each individually in nerve growth after spinal cord
injury [64].
While not specifically categorized as a growth factor, the purine nucleoside
inosine has been shown to promote axonal regeneration activating the protein kinase
Mst3b, a key component of the cell-signaling pathway through which trophic factors
regulate axon growth [65-67]. Combining inosine with various growth factors and
antagonists to inhibitors may improve the prospects for regeneration even further.
1.6.5 Research Tools and Methods: Antagonists to Nerve Growth
Inhibitors
A variety of effective strategies have been devised for blocking the effects of
inhibitory molecules in the CNS lesion environment. A multitude of experimental
approaches for blocking the myelin proteins are currently in use. Among them are
antibodies against the Nogo, MAG, and OMgp, antibodies against the Nogo Receptor, a
soluble Nogo receptor fusion protein to intercept myelin proteins before reaching the cell
surface, phospholipase C to release NgR from neuronal membranes, gene knockout,
siRNA gene knockdown, rho/ROCK inhibitors, and others. Many of these approaches
will likely work equally well in blocking effects of myelin proteins that also act through
the PirB receptor [68].
The glial scar has also been targeted with the chondroitinase ABC enzyme that
cleaves inhibitory chondroitin sulfate proteoglycans in the lesion environment [31].
1.7 Outline of this Research
This research will investigate the use of a collagen scaffold alone, or in
combination with neural progenitors or a soluble Nogo receptor for improving
histological outcome after penetrating brain injury. Type I collagen has been chosen for
this work based on its utility in peripheral nerve studies and its ability to be modified in
terms of composition (e.g. addition of glycosaminoglycans), architecture (e.g. pore size),
biocompatibility in other tissues, and cross-linking. Additionally, collagen does not
appear to have axon inhibitory properties like the native brain ECM consisting of
proteoglycans and glycosaminoglycans. The neural progenitors to be used have been
provided by Professor Fred Gage of the Salk Institute, and were harvested from the
hippocampi of adult rats. The use of adult cells eliminates the ethical concerns associated
with embryonic stem cells, and as already described, these cells can differentiate into
neurons, oligodendrocytes, and astrocytes. The soluble Nogo receptor has been selected
based on its ability to block Nogo, MAG, and OMgp to prevent them reaching
endogenous NgR or PirB receptor. This allows one to effectively block all 3 proteins and
both receptors with a single molecule, whereas antibodies would have to be targeted to
each individually.
The first part of this thesis will describe mechanical testing of collagen scaffolds of
varying collagen concentration. Through indentation testing and viscoelastic modeling,
the scaffold properties are compared to those of the in situ rat brain. A collagen scaffold
with properties reasonably similar to those of the rat brain is then chosen for in vivo
studies.
The second part of the thesis involves the characterization of a bilateral PBI lesion
in rats at 1 week at 5 week time points through histological, histomorphometric, and
immunohistochemical methods. Additionally, the implantation of collagen scaffolds is
evaluated for safety of the material in vivo and potential to fill the defect and interact with
surrounding tissue.
The third part of the thesis employs a larger biomaterial scaffold to attempt to
fully fill the PBI defect. The implantation of a collagen scaffold loaded with soluble
Nogo receptor (sNgR) is studied at 4 week and 8 week post-implantation time points and
compared with the scaffold alone.
The final part of the thesis investigates the implantation of a collagen scaffold
seeded with adult hippocampal progenitor cells. The survival of the cells is evaluated,
along with their potential for differentiation into neurons, astrocytes, oligodendrocytes,
endothelial cells, and macrophages.
Chapter 2: Viscoelastic Characterization of Rat
Cerebral Cortex and Type I Collagen Scaffolds for
Central Nervous System Tissue Engineering
2.1 Introduction
Mechanical testing of brain tissue has become an increasingly important topic in a
variety of fields. With the elevated incidence of traumatic brain injury (TBI) over the last
decade in the military conflicts in Iraq and Afghanistan, there has been an increased focus
on studying the brain's response to blasts, blunt trauma, and penetrating projectiles. In
these injuries, the mechanics of both the initial physical insult and secondary responses
such as rises in intracranial pressure due to hemorrhage and swelling are of interest [40,
69, 70]. For both experimental and computational modeling approaches [69], basic data
on the brain's bulk mechanical properties contribute to a more thorough understanding of
the brain injuries under study. Macromechanical modeling complements the ongoing
research into cellular mechanics of TBI-associated processes such as diffuse axonal
injury [71].
Brain mechanics are also highly relevant in neurosurgery for understanding of
pathological conditions [72, 73], as well as for modem procedures [73] and training
techniques [74]. The mass effect of a growing tumor has highly negative implications for
patient outcome due to compression of surrounding brain tissue with the potential for
herniation [75]. To accurately simulate the growth of a tumor and its subsequent
mechanical effects on the brain could be of clinical utility in estimating the risk of
herniation or other adverse outcomes. Such information could potentially help physicians
in determining the appropriate timing and course of action for individual patients. [76].
Similarly, the surgical management of patients with brain hemorrhage or edema (e.g.
after TBI) may be aided by additional knowledge of how the brain responds to increases
in volume and pressure within the skull [70].
Modeling of brain mechanics has an integral role in newer technologies for
neurosurgical training. While the opportunities for training in neurosurgical procedures
are obviously limited by various constraints of clinical and educational institutions,
simulated or "virtual" surgery has the potential to offer meaningful complimentary
training [74, 77]. With appropriate modeling of the brain mechanics, the simulated
surgery is intended to recreate with accuracy how the brain feels and responds to surgical
manipulations [78].
In the area of CNS regenerative medicine, there is emerging evidence that neural
cells may sense and respond to the mechanical stiffness of substrates they come in
contact with. Several results indicate that neurons prefer a soft substrate with stiffness
comparable to that of brain tissue, while astrocytes prefer stiffer surfaces. Using agarose
hydrogels, it was demonstrated that dorsal root ganglion neurons show an increasing rate
of neurite extension with decreasing matrix stiffness [79]. Similarly, neurons from the
mouse spinal cord show increased neurite branching on polyacrylamide gels as their
compliance increases [80]. In a mixed coculture of neurons and astrocytes on fibrin
scaffolds, it was found that scaffolds with stiffness similar to brain selected for neurons
over glia [81]. Both mesenchymal and neural progenitor cells have also displayed a
tendency to differentiate into neurons on compliant substrates [82, 83].
For the design of biomaterials intended for implantation into a CNS lesion, it may
then be beneficial to characterize the mechanical properties of the material and
understand how they relate to properties of the brain. While it is not supposed at this
point that a material should need to have properties identical to the brain to be effective,
one may nonetheless aim to create a biomaterial that approximately reproduces certain
aspects of the mechanical behavior. To demonstrate the characterization of such a
material and comparison with the brain, type I collagen scaffolds fabricated with varying
collagen concentrations are examined in this work. Similar scaffolds have been used in a
number of regenerative medicine applications involving skin [84], conjunctiva [85],
peripheral nerve [86], and spinal cord injury [87].
2.1.1 Indentation Testing
Standard compression, tension, or shear testing of very soft tissues can be
challenging due to the difficulty of preparing the specimens without damage and ensuring
that assumptions regarding friction and uniformity of the contact area are justified [88].
To test the cerebral cortex in one of these modalities requires removal of the brain from
the skull and a careful dissection to separate cortical tissue from deeper brain structures
without damaging the tissue. A convenient alternative is to use indentation testing, which
precludes the necessity of removing the brain from the skull and requires no physical
attachment of the tissue specimen to the testing device. Indentation solutions for
viscoelastic materials have also been recently developed [89, 90].
While creep testing may be more similar to some physiological scenarios in which
the brain or a biomaterial is under a nearly constant force, load control at very small
forces can be difficult to implement. The stress-relaxation testing conducted in this work
provides an alternative approach to investigate viscoelastic phenomena, but with the
relative ease of controlling displacement rather than force.
Indentation testing combined with linear viscoelastic modeling has not to our
knowledge been previously conducted for the collagen biomaterials used in this work.
While data on brain mechanical properties exists in the literature, it has been commented
that many studies show large discrepancies in results [91]. Further, there are relatively
few studies reporting specifically on properties of the rat brain. The rat is of particular
interest because of its prevalence in studies relating to a variety of brain injuries and
diseases. The data and methodology in this study may have utility for some of the
applications already mentioned, but will also add an independent verification of the only
published study on indentation of the rat brain [92]. This work adds the application of a
five-element Maxwell viscoelastic model to the brain indentation data. The model is
developed by expanding the published solution for spherical-tip indentation of a
viscoelastic material characterized by three linear elements in a standard viscoelastic
material configuration [89]. The three-element model is found in this work to be
insufficient for modeling the brain and scaffold relaxation responses, prompting the use
of the five-element model. The approach described provides a convenient method for
indentation testing and linear viscoelastic modeling of soft tissues and biomaterials.
While a linear model is generally not sufficient to describe the full range of behavior of
such materials [91], it is potentially useful over a limited range of strains and strain rates
[91, 93] and may aid in making simple comparisons between materials.
2.2 Experimental Methods
2.2.1 Rat Brain Preparation
Five adult female Lewis rats, whose primary use was for non-neurologic
experiments, were sacrificed by carbon dioxide asphyxiation. The top of the skull was
removed and the dura was resected to expose the frontal and parietal lobes. Tissue was
kept moist with phosphate buffered saline throughout the dissection and testing
procedure. All testing was completed well within the six hour time window before the
expected onset of significant tissue degradation [94, 95]. Each brain was tested at four
locations in the cortex (right and left frontal and parietal lobes), based on previous data
showing the cortex can reasonably be considered as homogeneous [91, 95]. For each
analysis parameter, an ANOVA was conducted to confirm that there was no effect of
indentation location before the separate measurements on the same brain were pooled
[95].
2.2.2 Collagen Scaffold Fabrication
Type I collagen scaffolds (0.5%, 0.75%, 1.0%, 1.5% weight:volume) were
fabricated from porcine microfibrillar collagen (Geistlich Biomaterials, Wolhusen,
Switzerland). A suspension of the collagen was first made in 0.001 N HCl, brought to
pH 3, and mixed with a stir bar for 20 minutes. The slurry was blended at 15,000 RPM
(Ultra Turrax T18 blender, IKA, Staufen, Germany) for 30 minutes at 4' C, brought
again to pH 3, and blended for an additional 2 hours. The slurry was then centrifuged for
10 minutes at 5500 RPM to remove air bubbles, and mixed with a pipette to ensure
homogeneity. The slurry was poured in a metal mold and placed into an AdVantage
Benchtop Freeze Dryer (VirTis, Gardiner, NY). The temperature was decreased at a
controlled rate to -20' C over 180 minutes and held at -20' C for 60 minutes.
Sublimation was conducted at a temperature of 0' C and pressure of 200 mTorr for 1020
minutes. Scaffolds were then dehydrothermally cross-linked overnight at 105' C under
vacuum. Additional chemical cross-linking was conducted using the water soluble agent
1-ethyl-3-(3-dimethylaminopropryl)carbodiimide hydrochloride (EDC) (Sigma-Aldrich
Inc, St. Louis, MO) with addition of N-hydroxysuccinimide (NHS) to increase the
reaction rate [96]. EDC cross-linking involves activation of carboxylic acid groups that
react with free amine groups in lysine residues to form amide bonds. Scaffolds were
hydrated with water prior to crosslinking for 2 hours with an EDC to NHS ratio of 5:2.
Six scaffolds of each collagen concentration underwent indentation testing.
2.2.3 Mechanical Testing
Mechanical tests were performed on a Zwick/Roell Mechanical Tester (Model
NO. Z2.5/TN1S, Zwick GmbH & Co) with a Zwick load cell (Part No. BTC-
LCO020N.PO 1). Scaffolds and brain specimens were indented with a 1 mm radius
hemispherical polyoxymethylene indenter to a depth of 0.5 mm at a displacement rate of
0.1 mm/sec, and held at constant displacement for 5 minutes to allow for relaxation.
Stress relaxation data was collected at a sampling rate of 10 Hz.
2.2.4 Signal Processing
Data processing was done using Matlab Version 7.6 (The MathWorks Inc.,
Natick, MA). The Matlab signal processing tool was used to perform low-pass filtering
on brain and scaffold data before application of the five element viscoelastic model using
the Matlab curve fitting tool.
2.2.5 Statistics
The StatView statistical package (version 5.0.0 1, SAS Institute Inc., Cary, NC)
was used for all statistical tests. Values are reported as mean standard error. One-
factor analysis of variance (ANOVA) was used to evaluate significance for the effect of
collagen concentration on mechanical properties of the collagen biomaterials. Post hoc
comparisons between scaffold groups were made using Fisher's protected least squares
differences. Unpaired t-tests were used to compare differences between brain properties
and those of the various scaffold groups. A p-value of 0.05 was used to establish
statistical significance.
2.3 Analytical Methods
2.3.1 Linear Elastic and Viscoelastic Modeling for Indentation of Rat Brain
and Collagen Biomaterials
To make an idealized characterization of the materials based on an elastic
modulus, one can employ the solution for indentation of an elastic half-space with a rigid
hemispherical indenter [92, 95, 97]. The load P is given as a function of the indentation
depth 6, the indenter radius R, the Poisson's ratio v, and the shear modulus G. For an
incompressible material (Poisson's ratio of 0.5), the shear modulus G for this loading
scenario is given in Equation 1. One can use Equation 1 to calculate idealized short term
and long term shear moduli from a stress-relaxation curve by evaluating the peak force at
the end of the loading phase and the approximately asymptotic load at the end of the
relaxation period [92, 95].
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Equation 1: Spherical-tip indentation solution for the shear modulus of an incompressible linearly
elastic material
To proceed with a viscoelastic characterization, one can apply the correspondence
principle [90]. The correspondence principle makes use of the fact that Laplace
transformed viscoelastic governing equations are of the same form as the elastic
governing equations. If the elastic solution is known, the transform of the viscoelastic
solution is obtained by substitution of time dependent (s-dependent) material properties
for the time independent parameters in the elastic equations. This procedure has been
demonstrated for both flat punch and spherical-tip indentation of viscoelastic materials
[89, 90]. In both cases, the viscoelastic material was modeled with three elements,
namely a spring in series with a parallel arrangement of a spring and dashpot. The
spherical-tip viscoelastic indentation solution for the three-element model is given in
Equation 2.
P(t) = E16 K E -E2)t E2
(9 El +E2 El +E2
Equation 2: Spherical-tip indentation solution of a viscoelastic material modeled with three linear
elements
It was attempted to use the above equations to fit the relaxation profiles of the brain and
scaffold data, with the understanding that a more complex model might be necessary.
While staying within the realm of linear viscoelasticity, a slightly more complex
model involving five elements was used to fit the data. The five-element model (Figure
1) is an example of a generalized Maxwell model, which may contain an arbitrary





Figure 2.1. Five-element viscoelastic model under load P and displacement s.
To extend the use of the correspondence principle from the three-element model
that Cheng et al. employed [89] to the five-element model, one may begin by deriving the
governing differential equation for the system in Figure 1 under load P and displacement
6. After writing equilibrium and geometric compatibility equations, Laplace transforms
are taken with a step displacement of magnitude 6o substituted for the general
displacement 6. The resulting relationship between the transformed load P and
transformed displacement is given in Equation 3.
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Equation 3: Laplace transformed relationship between load P and step displacement o.
To go from the load and displacement relationship to one between stress and strain, it is
first necessary to separate deviatoric from volumetric stress and strain. One can then
write a completely analogous relationship between deviatoric stress and strain [89, 90] in
which the spring constants are replaced by shear moduli G1, G2, G3, and the dashpot
constants replaced by viscosities 1q2, 113. The transformed relationship is given in
Equation 4, where &' is the transformed deviatoric stress and 5' is the transformed
deviatoric strain.
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Equation 4: Laplace transformed relationship between deviatoric stress and strain for a viscoelastic
material modeled with five linear elements.
For an elastic material, deviatoric stresses and strains are related by twice the shear
modulus. As a result, in the indentation solutions for elastic materials, the
correspondence is made with the viscoelastic material by replacing 2G with the time
dependent (s-dependent) term in parentheses in Equation 4. Taking the inverse Laplace
transform produces the solution in the time domain. For the elastic hemispherical
indentation solution in Equation 1, substituting for 2G, solving for P, and taking the
inverse Laplace transform with a step displacement input results in Equation 5a. The
solution for flat punch indentation is found by the same method and is given in Equation
5b. Note that the values ' 2/G2 and ' 3/G3 are the time constants for the two exponentials
in each equation.
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Equation 5a: Spherical-tip indentation solution for a viscoelastic material modeled with five linear
elements and subjected to a step displacement S0
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Equation 5b: Flat punch indentation solution for a viscoelastic material modeled with five linear
elements and subjected to a step displacement 6o
To determine the material properties from experimental stress-relaxation data, two
approaches are available. The first is to use a curve-fitting program, such as the
MATLAB curve fitting tool. The simplicity and accuracy of this method are preferable,
and as such it was used in this investigation. The second method is an explicit analytical
approach, making use of experimental values at particular time points and taking
advantage of particular aspects of the two-exponential behavior found in Equation 5a and
Equation 5b.
The analytical procedure will be briefly described for the flat punch indentation
solution. For approximations of step loading, the peak load is considered as being the
load at time 0. From Equation 5b, one can see that P(t=O) depends on the sum of the
shear moduli. Similarly, if one considers a time point near the end of relaxation
(approximated as t = o), then P(t=o) depends on G1 . Next, consider three time points ti,
t2, t3 in the relaxation phase. Choosing t2 and t3 to be relatively large, the term with G3 is
taken to be negligible by assuming it to have the shorter time constant. As a result, the
equations for P(0), P(o), P(ti), P(t2), and P(t 3) become sufficient for uniquely determining
G1, G2, G3, 912, and 113 to within an approximation consistent with the previous
assumption. G1 is determined directly from the experimental value P(oo) as seen in
Equation 6. To determine G2, one can use the ratio of P(t2 ) - PO) to find anP(t3 ) - P(o0)
expression for 2 , which can then be used with the expression P(t 2) - P(oo) to arrive at
q2
GEquation 7. With G2 and the ratio 2 known, 12 is calculated using Equation 8. For G3,
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P(t=0) is evaluated to obtain G3 in terms of G1 and G2 . With G1 and G2 already
determined, G3 is found from Equation 9. 113 is found in terms of G1, G2, and G3 , or P(oo),
G2, and G3 by manipulation of the expression for P(ti), yielding Equation 10.
G, = (04R9 0
Equation 6: Determination of G1 from estimation of the experimental value P(oo)
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Equation 7: Determination of G2 from experimental values P(t2), P(cc).
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Equation 8: Determination of 112 from experimental values P(t2), P(t3), and P(oo).
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Equation 9: Determination of G3 from experimental values P(O), P(t2), P(t3), and P(oo).
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Equation 10: Determination of s from experimental values
The five material parameters are thus approximately determined to fit the experimental
data with the five element model.
To characterize the brain and collagen biomaterials, the MATLAB curve fitting
program is used to determine the material parameters from the experimental relaxation
data for hemispherical indentation. As a means of comparing the two materials, as well
as comparing the brain data with other published literature, several measures are used.
First, a comparison of the idealized elastic shear modulus for the loading phase is
made based upon the elastic solution for spherical-tip indentation (Equation 1). The brain
data is compared to available literature values, while the brain and scaffolds are also
compared. Similarly, a comparison of the idealized long term shear modulus is made by
using the load at the end of the relaxation period in the same equation. Next, the five
material parameters G1 , G2, G3, 12, and 3 are compared for the materials. Their
relationship to the relaxation behavior of the materials is clarified by examination of the
two time constants of decay corresponding with ratios of shear moduli to viscosities.
Finally, the relaxation behavior of the materials is analyzed by calculating the extent of
relaxation relative to the maximum load attained during the indentation. Specifically, the
percent relaxation is calculated by taking 1 minus the ratio of the final load to the peak
load.
2.4 Results
2.4.1 Stress-Relaxation Behavior of Rat Brain and Collagen Scaffolds
The stress-relaxation curves for the collagen scaffolds showed similar general
viscoelastic behavior for the various collagen concentrations (Figure 2). Scaffolds
exhibited rapid relaxation upon cessation of the loading phase, with forces reaching
approximately asymptotic levels by the end of the 5 minute hold at constant
displacement. Higher force levels were observed for higher collagen concentrations, with
1.5% scaffolds having markedly larger forces than any other group. The rat brain also
showed the expected viscoelastic behavior with fast initial relaxation and forces
eventually reaching an approximate plateau. Rat brain curves appeared to have
maximum forces similar to some of the scaffolds, but lower forces at the end of
relaxation.
Attempts to fit experimental data with the three-element viscoelastic model in
Equation 2 revealed that a single exponential is not sufficient to accurately describe brain
or scaffold relaxation. This is consistent with previous indentation testing of porcine
brain [95], but had not been previously determined for the collagen scaffolds used in this
study. The five-element model, however, provided good fits (R2 generally above 0.90)
for both the brain and scaffold relaxation profiles (Figure 2). 0.5% scaffolds were not
able to be fit well due to resolution limitations of the load cell during data acquisition of
the relaxation phase.
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Figure 2.2. Representative brain (n=5) and collagen scaffold (n=6) relaxation data fitted with the
five-element viscoelastic model.
2.4.2 Idealized Short and Long Term Elastic Shear Moduli
The idealized elastic shear modulus for the loading phase increased significantly
with increasing collagen concentration (one-factor ANOVA; p<O.001; power--1.0) for the
scaffolds (Figure 3). Individual contrasts by post hoc testing also revealed significant
differences in the short term moduli of all scaffold groups. The rat brain was
significantly stiffer than the 0.5% (p<0.001) and 0.75% (p=0.013) scaffolds, and
significantly less stiff than the 1.5% scaffold (p<O.00 1). The difference between the
modulus of the brain and the 1.0% scaffold was not statistically significant. Moduli
ranged from 1.0 ± 0.04 kPa for the 0.5% scaffold up to 7.5 ± 0.37 kPa for the 1.5 %
scaffold.
The idealized long term elastic shear modulus (Figure 3) similarly showed a
significant effect of collagen concentration (p<0.001; power-l.0). The rat brain modulus
was significantly lower than 0.75% (p=0.002), 1.0% (p=0.002), and 1.5% (p<0.001)
scaffolds, but not significantly different from the 0.5% scaffold. Moduli ranged from 0.7
0.02 kPa for 0.5% collagen scaffolds to 4.2 +0.45 kPa for 1.5% scaffolds.
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Figure 2.3. Idealized short term and long term elastic shear moduli
2.4.3 Five-Element Model Parameters (G1, G2, G3, 112, 13)
The three shear moduli G1, G2, and G3 (Figure 4) in the five-element model all
increased with increasing collagen concentration for the scaffolds (p=0.002; power--1.0,
p<0.001; power-1.0, p<0.001; power-1.0, respectively). G1 values ranged from 1.6 ±
0.10 kPa for the rat brain to 7.9 ± 0.99 kPa for the 1.5% scaffolds, with the brain modulus
being significantly less than the 0.75% scaffold (p=0.003). G2 values ranged from 0.4
0.08 kPa for 0.75% scaffolds to 2.7 ± 0.18kPa for 1.5% scaffolds, with the rat brain
modulus of 2.0 ± 0.15 kPa being significantly greater than the 1.0% scaffold (p=0.005),
and significantly less than 1.5% scaffold (p=0.01 7 ). G3 values ranged from 0.5 ± 0.09
kPa for 0.75% scaffolds to 3.4± 0.35 kPa for 1.5% scaffolds, with the rat brain modulus
of 1.8±0.20 kPa again falling between 1.0% (p=0.001) and 1.5% (p=0.004) scaffolds.
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Figure 2.4. Shear moduli G1, G2, G3 for rat brain and collagen scaffold stress-relaxation data fit with
the five-element viscoelastic model
The viscosities 12 and 713 (Figure 5) also increased significantly with increasing
collagen concentrations (p<0.001; power-I for both). 12 ranged from 1.1 ± 0.19 kPa*s
for 0.75% scaffolds to 15.4 ± 0.98 kPa*s for 1.5% scaffolds, with rat brain viscosity of
11.0 ± 0.44 kPa*s being between 1.0% (p<0.001) and 1.5% (p=0.004) scaffolds. The
viscosity 13 ranged from 98.1 ± 27.1 kPa*s for 0.75% scaffolds to 648.2 ± 90.1 kPa*s for
1.5% scaffolds. Rat brain had a viscosity T3 of 148.7 ±6.8 kPa*s, which was
significantly less than the 1.5% (p<0.001) and 1.0% (p=0.02) scaffolds, but not
significantly different from 0.75% scaffolds.
Figure 2.5. Viscosities 112 (a) and 113 (b) for rat brain and collagen scaffold stress-relaxation data fit
with the five-element viscoelastic model
2.4.4 Relaxation Time Constants
The time constant -1= 12/G2 (Figure 6a) increased with increasing collagen
concentration for the scaffolds (p=0.006; power-0.89). 0.75% and 1.0% scaffolds had
respective 11 values of 3.0 ± 0.35 s and 3.3 ± 0.86 s, which were not significantly
different from each other, but were significantly lower than the 1.5% I value of 5.8 ±
0.19 s (p=0.003 and p=0.007, respectively). The brain had a r1 value of 5.7 ± 0.30 s,
which was significantly larger than -11 for the 0.75% (p<0.001) and 1.0% (p=0.042)
scaffolds, but not significantly different from the 1.5% scaffold. While T2= 113/G 3 (Figure
6b) did not vary significantly with collagen concentration for the scaffolds, the brain was
found to have a significantly shorter time constant than the 0.75% (p=0.046), 1.0%
(p=0.049), and 1.5% scaffolds (p<0.001).
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Figure 2.6. Time constants T1 (a) and T2 (b) for rat brain and collagen scaffold stress-relaxation data
fit with the five-element viscoelastic model.
2.4.5 Percentage Force Relaxation
The percentage relaxation (Figure 7) increased with increasing collagen
concentration for the scaffolds (p=0.001; power-0.98), with values of 27.4 ± 1.29%, 34.9
± 1.6%, and 44.1 ± 3.78% for 0.75%, 1.0%, and 1.5% scaffolds, respectively. Rat brain
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Figure 2.7. Percentage Relaxation (1-final load/peak load) for brain and scaffold materials.
2.5 Discussion
The application of viscoelastic modeling to collagen scaffold stress-relaxation
data acquired by indentation testing has not been previously reported. Studies that have
tested porous collagen and collagen-glycosaminoglycan scaffolds similar to those in this
work have done so in standard tension and compression configurations and reported
properties such as the Young's modulus [98, 99], tensile strength [100], and compressive
yield strength [98]. The published Young's modulus values are on the order of
approximately 1-6 kPa [98, 99] for scaffolds fabricated and tested under varying
conditions, which compares favorably with the short term moduli in this study.
The finding that the rat brain stress-relaxation curves can be fit relatively
precisely with two exponentials is consistent with previous data on stress-relaxation of
porcine brains [95]. It is observed that the relaxation is generally too steep in the initial
phase and too slow at the later time points to be fit well with a single exponential. We
have shown that type I collagen scaffolds exhibit similar behavior with respect to a stress-
relaxation profile that can be fit well by a minimum of two exponential curves.
The idealized short and long term shear moduli for the brain show reasonable
consistency with previously published indentation data on rat brain. The short term and
long term moduli found in this study were 2.9 ± 0.23 kPa and 0.8 ± 0.04, respectively,
while Gefen et al. reported values of 1.7 + 0.68 kPa and 0.5 0.25 kPa [92]. While
different studies of brain tissue have reported properties varying by as much as an order
of magnitude [91], the relative agreement here is encouraging. The consistency between
these two independent studies using different indenter radii and indentation depths gives
confidence in the reliability of the testing modality and the validity of assumptions made
in application of the theoretical indentation solution. Additionally, a recent study
conducted unconfined compression testing on the rat cerebral cortex and reported a value
of 1.0 + 0.17 kPa [98]. This result is not far from the values obtained through
indentation, and the lower value could be due to the use of a much slower displacement
rate.
In Figure 3 it can be seen that the 1.5% collagen scaffold has disproportionately
large short and long term moduli relative to the other scaffolds. This result can be
explained based on previous work that has modeled collagen scaffolds as open-cell foam
materials [101]. The open-cell foam model predicts that for such materials the Young's
modulus varies in proportion to the square of the relative density (defmed as the density
of the porous material divided by the density of the solid material from which it is made)
[99, 101]. This property, taken with recent data illustrating a linear increase in relative
density with increasing collagen concentration for scaffolds [99], suggests that the
Young's modulus should increase with the square of the collagen concentration. (It is
noted that the scaffolds in the study by Harley et al. included chondroitin 6-sulfate at a
proportion 10 times less by weight than collagen.) A plot of the short term shear
modulus found in this study versus the square of the collagen concentration produces a
linear relationship (R2=0.998) which is consistent with the predicted behavior (not
shown). The long term shear modulus shows a similar linear relationship (R2=0.997)
with the square of the collagen concentration.
Comparison of the brain idealized shear moduli with the collagen scaffolds
showed that the 0.5% scaffolds are much more compliant than the brain during loading,
while 1.5% scaffolds are much stiffer. 0.75% and 1.0% scaffolds had short term moduli
that were similar to the brain, with the 1.0% scaffold being most similar. The 0.5%
scaffold, however, had the most similar long-term modulus. While the relative
importance of the short and long term moduli with respect to cell behavior in a
biomaterial has yet to be elucidated, one can speculate that the scaffolds with properties
much stiffer than the brain may not be ideal for promoting primarily neuronal survival or
differentiation [81-83]. Additional considerations for use of these or similar biomaterials
might include the ease of handling, the in vivo degradation rate, and the resistance to pore
collapse. One can generally expect the stiffer scaffolds to have better handling
properties, slower degradation rates, and increased resistance to pore collapse due to
increased strut stiffness. The importance of such factors can vary significantly among
applications [86, 102-104].
In the five-element model, the parameter G1 was lower for the brain than for the
0.75%, 1.0%, and 1.5% scaffolds. G1 is related to the long term load, and illustrates that
the relaxation behavior for the brain differs substantially from the scaffolds by having a
lower force at the end of relaxation. This is essentially the same information as is found
from the idealized long term shear modulus, except that the modulus here relates to a
particular element in the viscoelastic model rather than a general solution for indentation
of an elastic material.
G2, G3 , 112, and 3 values for the brain were in between the 1.0% and 1.5%
scaffold. The viscosities relate to the relaxation behavior as one of the determinants of
the time constants of decay, while the moduli affect both the peak force during the
loading phase and also the relaxation behavior. Relative to the biomaterials, the model
parameters reflect the observation that the brain behaves more like the scaffolds of higher
collagen concentration in loading. In relaxation, however, there appear to be elements of
the behavior similar in some respects to the scaffolds of both higher and lower collagen
concentration. This is evident upon examination of the time constants themselves. The
time constant 11 for the brain is most similar to the 1.5% scaffold, with the 0.75% and
1.0% time constants being significantly shorter. T2 for the brain, however, is shorter than
0.75%, 1.0%, and 1.5% scaffolds. The modeling confirms the observation that the brain
generally relaxes to its long-term load faster than the scaffolds, even though the low
collagen concentration scaffolds have shorter r time constants that contribute to their
relatively steep decay immediately at the onset of relaxation.
A major difference between the brain and scaffold mechanical behavior is
illustrated in the results for percentage relaxation. The brain not only relaxes faster than
the scaffolds, but it relaxes by a much greater amount (i.e. to a much lower force). In
considering biomaterials for use in soft tissues, this result may be of particular interest.
Forces applied to the scaffold from cells or surrounding tissue are likely to be sustained
and of nearly constant magnitude. While the result of the material would be to creep in
that scenario, the phenomenon is similar to stress-relaxation. If it were desired to match
the behavior of the material to the tissue in which it was implanted, the degree of
relaxation would be an important factor to consider. For the scaffolds, the increase in
relaxation with increasing collagen concentration may be the result of increased water
uptake by the scaffold struts. Increasing the collagen concentration further would likely
achieve more relaxation, but the associated increase in stiffness might not be compatible
with the desired application. While there are clearly limitations in terms of how a
biomaterial can be manipulated to alter its mechanical properties, addition of other
materials to form a composite can be a helpful tool. As an example, elements of brain
extracellular matrix such as hyaluronic acid can be incorporated into a collagen scaffold
so that it more closely resembles the brain from a material standpoint [98, 105]. Addition
of hyaluronic acid could potentially increase the amount of water in the struts of a
hydrated scaffold, which may then result in a greater degree of relaxation without
increasing the stiffness as collagen has been shown to do. Adjusting the proportion of
each material offers a strategy to significantly alter the mechanical properties of the
scaffold [98].
2.6 Limitations
While the five-element viscoelastic model is shown to fit the stress-relaxation
curves reasonably well, it is limited in several respects. First, the brain is known to
exhibit nonlinear behavior [72, 106]. While a linear model can be useful for a restricted
range of strains and strain rates, a nonlinear model would be necessary to characterize the
material more accurately for a wide range of loading conditions [91]. The indentation
solution also relies on isotropy and homogeneity of the material, an assumption which
does not hold as one looks at other brain regions besides the cerebral cortex. Deeper
brain structures and white matter tracts such as the corpus collosum are known to exhibit
anisotropic mechanical behavior [91]. The model used in this work would thus be
inappropriate for describing behavior of other brain structures.
2.7 Conclusion
A five-element viscoelastic model has been used in conjunction with indentation
testing to characterize mechanical properties of rat cerebral cortex and various collagen
scaffold biomaterials. The brain and scaffolds both exhibit relaxation behavior that
cannot be accurately fit with a single exponential, but can be fit well with the two
exponentials of the five-element model. The brain exhibited behavior similar to the 1%
collagen scaffold in the loading phase, but was appreciably different from each scaffold
in the relaxation. The viscoelastic modeling identifies several parameters that can be
used to characterize materials and therefore potentially changed to arrive at a
mechanically suitable material for in vivo or in vitro work. For the purposes of CNS
tissue engineering, it remains to be seen how the variation in mechanical properties may
affect in vivo physiological responses to a particular biomaterial.
Chapter 3: Characterization of a Bilateral Penetrating
Brain Injury in Rats and Evaluation of a Collagen
Biomaterial for Potential Treatment
3.1 Introduction
Penetrating brain injury (PBI) represents a particularly severe form of traumatic brain
injury encountered in both military and civilian sectors. Projectiles (e.g. bullets,
shrapnel) that enter the brain result in very high mortality, but are not uniformly fatal
[107]. The path and velocity of the projectile are important determinants in whether an
individual will survive, with single hemisphere injuries, frontal lobe injuries and lower
projectile velocities associated with better outcomes [108-112]. While estimates of
overall mortality vary widely, one general estimate suggests up to 30% of individuals
suffering PBI in combat achieve long term survival [39]. Unfortunately, the treatment
options for patients remain limited mainly to surgical debridement [45] and medical
management of subsequent neurological symptoms [44]. With a more thorough
understanding of the physiology of PBI, potential therapies could be devised and
administered at the time of initial surgery and perhaps also in subsequent surgeries.
Previous studies of penetrating brain injury have actually fired projectiles into the
brains of animals including cats [113, 114], rabbits [115], and monkeys [116, 117].
Studies of these kinds have generally been discontinued, prompting the development of
different animal models.
Toward this end, a rat model to simulate a ballistic penetrating brain injury was
recently developed at the Walter Reed Army Institute of Research (WRAIR) [40]. The
key feature of PBI simulated by the model is the creation of a large temporary cavity
resulting from dissipation of kinetic energy while a projectile passes through the brain.
Various studies have demonstrated evidence [39] that the temporary cavity in PBI is
several times larger than the volume of tissue damaged solely from the path of the
projectile [45, 118, 119]. The injury model involves inserting a metal probe into the
brain to mimic the projectile path and inflating a balloon attached near the probe tip to
simulate the temporary cavity. The model has been shown to produce neurological
deficits, electrophysiological abnormalities, and histological features consistent with what
is known about PBI from larger animal models and from human pathology [40, 42, 43,
120]. It is noted that certain PBI features such as retained bone and metal fragments,
along with subsequent infectious processes, are not reproduced [121]. The model
nonetheless provides a useful method for studying several aspects of PBI
pathophysiology through the creation of a standardized cavitary defect.
Published work using the PBI model has focused on characterization of a frontal,
unilateral injury at time points up to 1 week post-injury. While one study evaluated
survival and behavioral outcomes following a bilateral injury [122], a histological
characterization similar to that of the frontal injury has not been conducted for a bilateral
injury. Additionally, the progression of the PBI lesion several weeks after the injury has
not been studied. This work aims to characterize the bilateral PBI injury at 1 week and 5
week time points using histomorphometric and immunohistochemical methods. It is
observed that the permanent cavity that eventually forms in the brain as the result of PBI
lends itself to the possibility of treatment through implantation of a biomaterial. The
biomaterial might act as a suitable delivery vehicle for pharmacological or cellular
therapeutic agents to mitigate injury progression or promote regeneration. As a
preliminary step towards developing such a treatment, this work will also evaluate the
effects of implanting a preformed collagen scaffold either immediately or 1 week after
the injury.
3.2 Materials and Methods
3.2.1 Experimental Design
Four groups of animals were used in this study, with all undergoing surgical
administration of a bilateral penetrating brain injury. The injury involved inflation of the
PBI balloon to a volume equal to approximately 10% of the rat brain volume. Group 1
was administered the injury and allowed to survive for 1 week before sacrifice. Group 2
was administered the same injury but was then implanted with a type I collagen scaffold
and sacrificed after 1 week. Group 3 underwent the injury, but was allowed to survive
for 5 weeks. It is noted that at 1 week post-injury, the Group 3 animals underwent a
sham surgery to serve as controls for Group 4. Group 4 underwent the injury, and 1 week
later had a second surgery to implant a collagen scaffold. Group 4 animals were
sacrificed 4 weeks after implantation of the scaffold (5 weeks post-injury). The
experimental groups are summarized in Table 1.
Table 1: Experimental Groups
Group 1 (n=5) Group 2 (n=5) Group 3 (n=6) Group 4 (n=5)
1 st surgery Injury without 10% injury Injury without Injury without
intervention with scaffold intervention intervention
implantation
2" surgery N/A N/A Sham Scaffold
implantation implantation 1
surgery 1 week week post-
post-injury injury
Sacrifice time 1 week 1 week 5 weeks 5 weeks
(post-injury)
3.2.2 Penetrating Brain Injury Apparatus
Technical details of the PBI apparatus (Dragonfly Inc., Ridgeley, WV) have been
described in several publications [40, 42]. Briefly, the apparatus consists of components
including a balloon-tipped probe, a stereotaxic frame (Kopf, Tujunga, CA), a piston-
cylinder pneumatic device, and a pendulum. The pendulum is dropped under gravity to
drive the piston, forcing the air in the cylinder through tubing of smaller diameter and
generating a pressure impulse to rapidly inflate the balloon. The balloon, which takes the
shape of an ellipsoid, has been reported to remain inflated on average for less than 6.6
Ms.
3.2.3 Collagen Scaffold Fabrication
Type I collagen scaffolds (1.0% weight:volume) were fabricated from medical grade
porcine microfibrillar collagen (Geistlich Biomaterials, Wolhusen, Switzerland). A
suspension of the collagen was first made in 0.001 N HCl, brought to pH 3, and mixed
with a stir bar for 20 minutes. The slurry was blended at 15,000 RPM (Ultra Turrax T18
blender, IKA, Staufen, Germany) for 30 minutes at 4' C, brought again to pH 3, and
blended for an additional 2 hours. The slurry was then centrifuged for 10 minutes at
5500 RPM to remove air bubbles, and mixed with a pipette to ensure homogeneity. The
slurry was poured in a metal mold and placed into an AdVantage Benchtop Freeze Dryer
(VirTis, Gardiner, NY). The temperature was decreased at a controlled rate to -40' C
over 180 minutes and held at -40' C for 60 minutes. Sublimation was conducted at a
temperature of 0' C and pressure of 200 mTorr for 1020 minutes. Scaffolds were then
dehydrothermally cross-linked overnight at 1050 C under vacuum. Biopsy punches were
used to cut scaffolds 3 mm in diameter and approximately 3 mm in thickness for
implantation. Published work using similar scaffolds has determined the pore size to be
approximately 100-150 ptm. Similar collagen scaffolds have been used in several
published studies from our research group.
3.2.4 Surgical Procedure and Animal Care
24 male Sprague-Dawley rats were used in this study. All procedures were approved by
the Boston VA Healthcare System Institutional Animal Care and Use Committee.
Animals were shaved, anesthetized with isoflurane, and positioned in a stereotaxic
frame where the anesthetic delivery was maintained through a nosecone. A circulating
water heating pad was used to maintain body temperature throughout the surgery and also
for several hours during the post-operative recovery. Heart rate and blood oxygen
saturation were monitored from a probe on the foot during the procedure.
After sterilizing the skin with 13% povidone iodine solution, a midline incision
was made along the top of the head to expose the skull, followed by a lateral incision
extending from the posterior aspect of the midline incision and passing just anterior to the
left ear (Figure 3.1a). With the top of the skull and the left side of the head exposed, a
portion of the left temporalis muscle was excised with care taken to avoid damaging the
temporal branch of the facial nerve (Figure 3. lb). With the lateral aspect of the skull
exposed, a 3 mm diameter window was drilled in the skull at a position 1 mm anterior to
bregma and 3 mm ventral to bregma (Figure 3. 1c). The PBI probe was then positioned
with the tip at the surface of the brain (Figure 3.1 d) before pausing to briefly ensure
stability of the animal's vital signs.
The PBI probe was then inserted into the brain, with the tip advancing 10 mm
from the surface of the left hemisphere into the right hemisphere. The PBI balloon was
inflated to a diameter of 6.3 mm to create an injury encompassing approximately 10% of
the rat brain volume. It is noted that the balloon is several mm proximal to the tip of the
probe, such that the balloon inflation is predominately in the left hemisphere despite the
probe tip being in the right hemisphere. This scenario mimics a projectile entering the
left hemisphere and dissipating its kinetic energy before coming to rest in the right
hemisphere. Following the balloon inflation, the probe was retracted from the brain and
bleeding was controlled using Gelfoam. Animals in Group 2 underwent implantation of
a cylindrical collagen scaffold 3 mm in diameter and 3 mm thick into the defect at this
time. Groups 1, 2, and 3, had no intervention. The cranial window was covered
(Figure 3.1 e) with a Bio-Gide collagen membrane (Geistlich Biomaterials, Wolhusen,
Switzerland) and the surgical incision was closed with a 4-0 suture (Figure 3. If).
Figure 3.1. PBI Surgical Procedure. a) Lateral aspect of the head with the temporalis muscle
exposed. b) Lateral surface of the skull exposed with part of the temporalis muscle excised. c)
Cranial window though which the PBI probe will be inserted. d) PBI probe in place just prior to
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insertion into the brain. e) Collagen membrane covering the cranial window following the injury. f)
Incisions closed with 4-0 sutures.
1 week after the injury, animals in Groups 3 and 4 underwent a second surgery. A
second incision was made parallel to the lateral incision from the first surgery
(Figure 3.2a), enabling access to the defect site (Figure 3.2b). After removing the
collagen membrane covering the cranial window (Figure 3.2c), the lesion site was
exposed (Figure 3.2d). Group 4 animals had a collagen scaffold implanted at this time
(Figure 3.2e), while Group 3 animals had only the surgery without scaffold implantation.
The cranial window in each case was covered again with a collagen membrane
(Figure 3.2f) and the incision closed with a 5-0 suture.
Following all surgeries, animals were allowed to recover in warmed cages with
additional oxygen administered through a nose cone. Food and water were provided at
bedding level. Animals were initially placed on their side within the cage while
recovering from anesthesia and the surgical trauma. Buprenorphine (0.05 mg/kg) was
given for pain relief, while Cefazolin (20 mg/kg) was given to prevent infection.
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Figure 3.2. Collagen Scaffold Implantation Surgery. a) Incision to expose the site of the cranial
window. b) Scar tissue covering the collagen membrane and cranial window. c) Cranial window
exposed. d) Cranial window exposed (different animal). e) Implantation of the collagen scaffold into
the defect. f) Collagen membrane covering the cranial window prior to closing the incision
3.2.5 Animal Sacrifice and Specimen Processing
Before sacrifice, animals were deeply anesthetized with an intraperitoneal injection of
sodium pentobarbital (150 mg/kg). When all reflexes were lost, surgical scissors were
used to cut through the skin, muscle, and thorax to expose the heart. Animals were then
transcardially perfused (Figure 3.3) with 150 mL cold heparanized PBS (20 units/mL)
followed by 250 mL cold 4% paraformaldehyde solution (USB corporation 19943,
Cleveland, OH). Brains were extracted and immersed in 4% paraformaldehyde for 2-3
days at 4' C. Brains were processed through reagent alcohol (70% - 10 min, 80% - 90
min, 95% - 2 x 90 min, 100% - 2 x 90 min, 100% - 90 min under vacuum), xylene (3 x 90
min), and paraffin (2 x 180 min under vacuum, 58 C). Samples were then embedded in
paraffin and sectioned on a microtome at 5 pim. Sections were taken at approximately 1
mm intervals spanning the lesion. Slides were dried on a warmer at 60' C for several
hours.
Figure 3.3. Transcardial Perfusion
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3.2.6 Histology and Immunohistochemistry
Sections were stained with hematoxylin and eosin for histomorphometric analysis and for
general histologic observation of the injury. Slides were first deparrafmized (xylenes: 2 x
5 min, 100% reagent alcohol: 2 x 3 min, 95% alcohol: 2 x 2 min, 80% alcohol 1 x 1 min)
and rehydrated (5 min water rinse). Slides were stained in Gill's hematoxylin for 3
minutes, rinsed for 5 minutes, and stained in eosin for 45 seconds. Slides were processed
through 95% alcohol (2 x 2 min) and xylenes (2 x 2 min) before being coverslipped with
Cytoseal.
The fluorescent dye Fluoro-Jade C (Millipore AG325) was used for visualization
of degenerating in the thalamus. Sections from approximately 2.5 mm posterior to
bregma were deparrafinized and rehydrated prior to incubation in 0.06% KMnO 4 (Sigma
223468) for 20 minutes. After 3 rinses in deionized water, slides were then stained with
0.00015% Fluoro-Jade C solution for 20 minutes and rinsed 3 more times in water.
Slides were dried on a warmer at 600 C for 10 minutes, placed in xylene for several
minutes, and coverslipped with Cytoseal mounting medium.
Antibodies, dilution factors, and antigen retrieval methods used for
immunohistochemistry are summarized in Table 2. The staining procedure was
conducted at room temperature. Following deparrafinization, rehydration, and antigen
retrieval, slides were rinsed with wash buffer (Dako S3006) containing TBS and 0.05%
Tween 20. Slides were blocked for 2 hours with Dako protein block (Dako X0909) prior
to addition of the primary antibody for 2 hours. Following 3 rinses with wash buffer, the
secondary antibody was added for 1 hour. After 3 more rinses, a 100 ng/mL solution of
the fluorescent DNA stain 4',6-diamidino-2-phenylindole (DAPI) was added for 30
minutes. 3 final rinses with wash buffer were performed and the slides were then placed
in TBS for 3 minutes. The slides were transferred to a 0.1% solution of Sudan Black
(Sigma 199664) dye for 20 minutes in to reduce tissue autofluorescence. Following 3
rinses in TBS, slides were coverslipped with Immu-mount aqueous mounting medium
(Thermo Scientific 9990402).
Table 2: Immunohistochemistry reagents (Abbreviations: rb (rabbit), ms (mouse), gt (goat),
10 Antibody Source Retrieval Dilution 2' Antibody
GFAP (rabbit Dako 0.1% Protease 1:500 Dylight 488 donkey
polyclonal) (Z0334) XIV 25 min anti-rabbit IgG (Jackson
(Sigma P5147) ImmunoResearch 711-
485-152)
Von Willebrand Dako 0.1% Protease 1:100 Dylight 488 donkey
Factor (rabbit (A0082) XIV 40 min anti-rabbit IgG (Jackson
polyclonal) (Sigma P5147) ImmunoResearch 711-
485-152)
Doublecortin Santa Cruz Citrate buffer pH 1:100 Dylight 488 donkey
(goat (sc-8066) 6, 2 min 1200 C anti-goat IgG (Jackson
polyclonal) (Dako S 1699) ImmunoResearch 705-
485-003)
CD68 (mouse Serotec 0.1% Protease 1:200 Dylight 549 donkey
monoclonal (MCA341R) XIV 20 min anti-mouse IgG
IgG) (Sigma P5147) (Jackson
ImmunoResearch 715-
505-150)
NeuN (mouse Millipore Citrate buffer pH 1:200 Dylight 549 donkey
monoclonal (MAB 377) 6, 1 min 1200 C anti-mouse IgG
IgG) (Dako S 1699) (Jackson
ImmunoResearch 715-
505-150)
CNPase (mouse Abcam Citrate buffer pH 1:500 Dylight 549 donkey
monoclonal (ab6319) 6, 20 min 950 C anti-mouse IgG
IgG) (Dako S1699) (Jackson
ImmunoResearch 715-
505-150)
CS56 (mouse Sigma 0.1% Protease 1:100 Rhodamine donkey anti-
monoclonal (C8035) XIV 40 min mouse IgM (Jackson
IgM) (Sigma P5147) ImmunoResearch 715-
025-020)
3.2.7 Imaging
Light microscope images were taken with an Olympus camera interfaced with a Olympus
BX51 microscope, while fluorescent images were captured an Olympus DP71 camera
interfaced with an Olympus BX60 microscope. Adobe Photoshop CS3 was used for
minor image processing procedures such as cropping and adjustment of levels to reduce
background [123].
3.2.8 Histomorphometric Analysis
Lesion area was demarcated in hematoxylin and eosin stained sections at approximately 1
mm intervals spanning the lesion. The lesion was defined by areas of obvious necrosis
with lack of cellularity, along with regions of dense macrophage infiltration, hemorrhage,
gliosis, and vacuolization. A linear interpolation was used to reconstruct an approximate
volume, with the volume between sections being equal to the average of the areas
multiplied by the distance between them.
3.2.9 Statistics
Numerical values are reported at mean ± standard error, and all statistical analysis was
performed using Statview (version 5.0.01, SAS Institute Inc., Cary, NC). Unpaired t-
tests were used to compare differences between experimental groups, with a p-value of
0.05 used for determining statistical significance.
3.3 Results
3.3.1 Animal Survival, Recovery, and Qualitative Behavioral Observations
21 out of 24 animals survived for the intended duration of their experimental groups. 2
of the 3 deaths occurred during the surgery to administer the injury, while the third
occurred the day after the injury. All animals undergoing a second surgery (Groups 3 and
4) survived with no apparent adverse effects of the surgery or the implanted biomaterial.
Following administration of the injury, animals generally remained on their side
for 1-3 hours before gradually righting themselves and withdrawing from the oxygen
nosecone. Variability was observed in the degree to which animals would then begin
grooming, ambulating, and eating. As recovery progressed several days after injury, the
animals generally groomed themselves well and kept the incision site clean (Figure 3.4a).
Animals undergoing a 2nd surgery similarly kept both incision sites very clean
(Figure 3.4b). No signs of infection were apparent in any of the animals.
Figure 3.4. Incision sites following surgery. a) 1 week post-injury. b) 5 days after 2nd surgery
(different animal)
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Figure 3.5 shows the average weight progression for each group as a percentage
of their weight at the time of the first surgery. Animals in Group 1 (Figure 3.5a) and
Group 2 (Figure 3.5b) typically lost weight in the first 2-3 days after the injury, but
thereafter recovered and continued to maintain or gain weight for the duration of the
study. In each group, the average weight started to increase by the 3rd day after surgery.
Animals in Group 3 (Figure 3.5c) and Group 4 (Figure 3.5d) showed similar weight loss
following injury, but generally lost little or no weight after the second surgery.
Weight Progression After PBI: Group I Weight Progression After PSI: Group 2
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weight on average in the first 2 days after surgery, and thereafter began to gain weight again. b)
Animals in Group 2 showed a similar trend to Group 1. c) Animals in Group 3 maintained their
weight on average after the second surgery (Day 8). d). Animals in Group 4 showed a similar trend
to those in Group 3.
Following the injury, animals consistently showed a decreased ability to use their
right forelimb for grasping food while eating. Additionally, a slight tremor of the head
was observed in some animals. Both the forelimb deficit and the tremor appeared to
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mostly resolve within 3-4 days based on observation of the animals eating, grooming, and
ambulating normally. It is likely, however, that sensitive functional and behavioral tests
would detect some degree of persistent deficit even at later time points.
3.3.2 Lesion Characteristics and Volume
The site of the lesion was very obvious upon observation of the brain after extraction
(Figure 3.6a). Histologically, the bilateral PBI was observed after 1 week to cause a large
amount of damage to the left striatum, as well as lesser injury to elements of sensory and
motor cortex, corpus callosum, external capsule, and the lateral ventricles (Figure 3.6b).
In Group 1 and Group 2, the lesion at 1 week consisted of a large amount of necrotic
debris (Figure 3.6c and Figure 3.6d), with dense infiltration of macrophages, areas of
hemorrhage, and some areas of vacuolization within the striatum. The size of the cavity
was smaller than the entire lesion, as much of the dead tissue had not yet been cleared.
At 5 weeks, however, Groups 3 and 4 revealed that the cavity had become much
larger as most of the necrotic debris had been removed (Figure 3.7b). Injured structures
were largely same, though the injury appeared to have expanded to include virtually the
entire left striatum. Although a few areas of necrosis persisted within the cavity and
notably at the edge of the corpus callosum (Figure 3.7c and Figure 3.7d), most of the
remaining tissue appeared viable and without dense macrophage infiltration.
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Figure 3.6. H&E Histology 1 Week after PBI (Group 1). a) PBI lesion evident in the extracted brain
from a Group 1 animal. b) H&E coronal section showing damaged regions of cortex, striatum,
lateral ventricle, external capsule, and corpus callosum after 1 week. c) Necrotic tissue being cleared
by macrophages. d) Higher magnification image showing erythrocytes and engorged macrophages
in the lesion site.
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Figure 3.7. H&E Histology 5 Weeks after PBI (Group 3). a) PBI lesion after 5 weeks in the
extracted brain of a Group 3 animals. b) H&E image showing the large PBI cavity in the left
hemisphere at 5 weeks. c) Degeneration in the corpus callosum at 5 weeks. d) Higher magnification
of the corpus callosum showing necrotic white matter with macrophage infiltration.
The volume of the bilateral PBI lesion was calculated to be 51.2 ± 3.7 mm3 and
51.9 ± 4.4 mm3 after 1 week in Groups 1 and 2, respectively. At 5 weeks, the Group 3
and 4 volumes were 65.9 ± 2.7 mm 3 and 85.1 ± 12.9 mm3, respectively. Lesion volumes
are summarized in Figure 3.8. Comparisons between groups revealed that the lesion
volume at 5 weeks in Group 3 was significantly greater than the volume at 1 week in
Group 1 (p = 0.010). Similarly, the Group 3 volume was significantly greater than that of
Group 2 (p=0.020). The Group 4 volume was significantly greater than those of Group 1
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Figure 3.8. PBI Lesion Volumes. Group 3 and 4 volumes were significantly greater than Group 1
(p=0.010, p=0.036, respectively) and Group 2 (p=0.020, p=0.041, respectively) volumes.
3.3.3 Scaffold Localization and Cellular Infiltration
Scaffolds in Group 2 generally remained intact within the lesion site 1 week after
implantation (Figure 3.9b). The volume of the scaffold appeared to fill most, but not all
of the lesion site. The scaffolds were generally localized to the injured regions in the
ipsilateral striatum and cortex, and were often in contact with some tissue that appeared
viable. The scaffolds were observed to have open pores without apparent degradation of
the scaffold struts. Cells from the surrounding tissue appeared to have infiltrated the
scaffolds in relatively small numbers (Figure 3.9c). Many of the cells had morphology
similar to that of macrophages in the surrounding tissue. Erythrocytes were also
observed within the scaffolds (Figure 3.9d).
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Figure 3.9. H&E Histology 1 Week after PBI and Scaffold Implantation (Group 2). a) Extracted
brain showing a collagen scaffold in the PBI lesion. b) H&E histology showing the collagen scaffold
within the PBI lesion. c) Cellular infiltration at the superior edge of the scaffold. d) Higher
magnification view showing cells along the scaffold struts
Group 4 scaffolds were observed to be much smaller than the size of the lesion at 5
weeks, and did not come close to filling the volume of the cavity (Figure 3. 1Oa and
Figure 3. 10b). The scaffolds were also poorly integrated into the surrounding tissue, with
only a fraction of their surface areas contacting viable tissue. The scaffolds were found
localized to the lateral aspect of the lesion, and in 2 cases were partially adhered to the
inside of the skull. One of the adhered scaffolds was not recognized as such, and was lost
. ................................... .....................   
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during extraction most likely due to inadvertently removing it with a portion of the skull.
In the remaining 4 samples, the scaffold pores were open and there was some cellular
infiltration which appeared qualitatively similar to Group 2 (Figure 3.1 Oc and
Figure 3. 10d). The integrity of the scaffolds appeared to be maintained with no obvious
signs of degradation present.
Figure 3.10. H&E Histology 4 Weeks after Scaffold Implantation (Group 4). a) Extracted brain
with a collagen scaffold in the lesion site. b) H&E histology showing a collagen scaffold at the lateral
edge of the PBI cavity. c) Cellular infiltration along the superior edge of the scaffold. d) Higher
magnification image showing cells within the scaffold
3.3.4 Glial Scarring and Inflammation: GFAP, CS56 and CD68
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GFAP staining showed reactive astrocytes surrounding the lesion in all groups. At 1
week (Group 1 and 2), GFAP reactivity was absent within much of the necrotic lesion
while being primarily localized outside the collection of inflammatory cells within and
bordering the necrosis (Figure 3.11). There was little GFAP reactivity seen within the
scaffold in Group 2 (Figure 3.12).
Figure 3.11. GFAP Staining Surrounding the PBI Lesion after 1 Week (Group 1). a) H&E histology
showing a PBI lesion after 1 week. b) GFAP staining surrounding the lesion site.
Figure 3.12. GFAP Staining Surrounding the Implanted Collagen Scaffold after 1 Week (Group 2).
a) H&E image showing a collagen scaffold within the defect site after 1 week. b) GFAP reactivity
surrounding the lesion, with very little staining within the scaffold.
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At 5 weeks (Groups 3 and 4), GFAP reactivity bordered most of the cavity with a band of
intense staining (Figure 3.13). There was, however, variability in the degree of gliosis
surrounding the lesion at various locations. Figure 3.14 illustrates a relatively thick band
of gliosis surrounding the cavity at a coordinate near the anterior boundary of the lesion.
GFAP expression in Figure 3.14 also appears to be upregulated throughout much of the
ipsilateral hemisphere, and not only in the immediately vicinity of the cavity. There were
scattered GFAP positive cells at a low density within the scaffold of Group 4
(Figure 3.15).
Figure 3.13. GFAP Reactivity Bordering the PBI Cavity at 5 Weeks (Group 3). a) H&E image of
the PBI lesion after 5 weeks. b) GFAP reactivity along the superior edge of the cavity.
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Figure 3.14. GFAP Reactivity Near Anterior Aspect of Lesion at 5 weeks (Group 3). a) H&E image
of the anterior portion of the PBI cavity. b) GFAP staining bordering the cavity and extending
throughout much of the ipsilateral hemisphere.
Figure 3.15. GFAP Reactivity Surrounding the Implanted Collagen Scaffold (Group 4). a) H&E
histology showing an implanted scaffold. b) GFAP reactivity surrounding the lesion with a
relatively small amount of staining within the scaffold
While the degree of GFAP reactivity within the scaffolds of Group 2 and Group 4
was low relative to the surrounding tissue, astrocytes could be detected along the scaffold
struts at high magnification (Figure 3.16). The density of astrocytes in Group 2 was 12.1
± 2.0 cells/mm2 , which was significantly less (p=0.0 5 3 ) than the density of 19.0± 2.1 in
Group 4 (Figure 3.17).
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bFigure 3.16. GFAP positive astrocytes within the collagen scaffolds of Group 2 and Group 4. a)
Astrocytes within a scaffold after 1 week (Group 2). b) Astrocytes within a scaffold after 4 weeks
(Group 4). Green: GFAP, Blue: DAPI






Figure 3.17. GFAP Cell Density in Collagen Scaffolds (Group 2 and Group 4). The density of
astrocytes in Group 4 scaffolds was significantly greater than in Group 2 scaffolds (p=0.053).
CS56 staining showed relatively high background staining of the normal
extracellular matrix, but also demonstrated increased staining around the border of the
lesion (Figure 3.18).
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Figure 3.18. CS56 Reactivity Surrounding the PBI Lesion at 5 Weeks (Group 3). a) H&E image of a
PBI lesion after 5 weeks. b) Increased CS56 reactivity bordering the PBI cavity.
CD68 staining confirmed the phenotype of many of the inflammatory cells as
macrophages. Additionally, widespread reactivity could be observed throughout regions
including the cortex, striatum, external capsule, and corpus callosum (ipsilateral and
contralateral). The macrophage infiltrate was very dense at 1 week (Figure 3.19), while
far fewer macrophages were observed at 5 weeks. However, at 5 weeks CD68 reactivity
persisted both near the lesion and remotely in white matter tracts.
In Group 2 and Group 4, CD68 staining showed that many of the cells that had
infiltrated the scaffold were macrophages. The density of CD68-positive macrophages in
Group 2 scaffolds was 50.5 ± 7.2 cells/mm 2, while the density in Group 4 scaffolds was
39.0 ± 6.0 cell/mm 2 . The difference was not statistically significant.
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Figure 3.19. CD68 Staining of the PBI Lesion after 1 Week (Group 1). a) H&E image of a PBI
lesion. b) Numerous CD68 positive macrophages in the lesion site at 1 week.
Figure 3.20. CD68 Staining of PBI Lesion After 5 weeks (Group 3). a) H&E image of a PBI lesion at
5 weeks. b) Reduced CD68 staining at 5 weeks relative to the lesion at 1 week. Staining is evident
around the border of the lesion and in the small amount of remaining cellular debris.
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Figure 3.21. CD68 Staining within a collagen scaffold after 1 week (Group 2). a) H&E image of
collagen scaffold within a PBI lesion after 1 week. b) CD68 staining of macrophages within the
collagen scaffold (Red: CD68, Blue: DAPI)
Figure 3.22. CD68 Staining within a collagen scaffold after 4 weeks (Group 4). a) H&E image of a
collagen scaffold within a PBI lesion. b) CD68 staining of macrophages within the collagen scaffold
(Red: CD68, Blue: DAPI)
3.3.5 Blood Vessels and Endothelial Cells: Von Willebrand Factor
VWF staining displayed many blood vessels within and surrounding the lesion site in
response to the injury. At 1 week, vessels were present throughout the areas of necrosis
(Figure 3.23), while at 5 weeks many vessels bordered the large lesion cavity
(Figure 3.24). An occasional VWF positive cell or vessel was found within the scaffolds
of Group 2 (Figure 3.25a), with density being 0.9 + 0.4 per mm2. A small number of
VWF positive cells/vessels was also found in Group 4 (Figure 3.25b), with the density
being 4.7 ±2.1 per mm2 . The difference between Groups 2 and 4, however, did not reach
statistical significance (p=0.09).
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Figure 3.23. VWF staining of blood vessels within the PHI lesion after 1 week (Group 1). a) H&E
histology of a PBI lesion after 1 week. b) Numerous VWF positive blood vessels in the lesion site.
Figure 3.24. VWF staining of blood vessels bordering the PBI cavity after 5 weeks (Group 3). a)
H&E image of a PBI lesion after 5 weeks. b) Blood vessels along the border of the PBI cavity.
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Figure 3.25. VWF staining in collagen scaffolds after 1 week (Group 2) and 4 weeks (Group 4). a)
VWF positive cells/vessels in a collagen scaffold from Group 1. The approximate scaffold border is
indicated with a white dotted line. b) VWF cell/vessel in a collagen scaffold from Group 4.
3.3.6 Neuronal Degeneration: Fluoro-Jade C
A large number of degenerating neurons were present in the thalamus 1 week after the
injury in Groups 1 and 2. While individual neurons stained brightly (Figure 3.26c and
Figure 3.26d), there was also diffuse reactivity throughout areas of neuropil and
extracellular matrix (Figure 3.26b). Regions of the thalamus showing evidence of
degeneration included the laterodorsal, mediodorsal, ventrolateral, ventromedial, ventral
posteromedial, and ventral posterolateral nuclei. Additionally, white matter reactivity
was present throughout much of the ipsilateral internal capsule. The positive staining of
neuronal cell bodies was generally restricted to the ipsilateral hemisphere, though a few
degenerating cells could also be found in the contralateral thalamus. Groups 1 and 2
looked qualitatively similar in terms of the regions and approximate number of cells that
were degenerating.
At 5 weeks post-injury, far fewer FJC positive cells were observed in the relative
to 1 week. Only a few scattered cells could be detected in the thalamus, though there was
some persistent staining of the neuropil and extracellular matrix. Additionally, white
matter reactivity in the internal capsule persisted.
Figure 3.26. Fluorojade staining of degenerating neurons 1 week after PBI (Group 1). a) H&E
section from Group 1 including thalamic nuclei. b) Low magnification Fluorojade C staining
showing reactivity in the thalamus and internal capsule. c) Neuronal cell bodies in the thalamus
staining positively. d) Higher magnification image of degenerating neurons in the thalamus
3.3.7 Oligodendrocytes and Myelinated Axons: CNPase
At 1 week, there was a distinct absence of CNPase staining in and immediately around
the lesion site (Figure 3.27b). A clear discontinuity was observed in the corpus callosum
(Figure 3.27b), a white matter structure that would normally pass through the lesion area.
Superior regions of the striatum that would normally have white matter bundles also
showed an absence of staining. More inferior areas of the striatum showed preserved, but
abnormal staining of white matter bundles. Relative to the contralateral hemisphere
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(Figure 3.27d), the damaged white matter appeared to be filled with circular areas that did
not stain (Figure 3.27e). Farther from the lesion, the CNPase staining regained an
appearance similar to the contralateral hemisphere.
At 5 weeks, with most of the necrotic tissue of the lesion cleared, CNPase staining
was observed around the borders of the lesion area (Figure 3.28b). In some cases
CNPase positive axons traversed a path immediately along the edge of the cavity and
possibly overlapping with areas of gliosis (Figure 3.28c).
While no CNPase staining was observed within the borders of the scaffolds in
Groups 2 (Figure 3.29b) and 4 (Figure 3.30b), the CNPase staining did pass directly
along the scaffold edges in some cases.
Figure 3.27. CNPase staining 1 week after PBI (Group 1). a) H&E histology of a PBI lesion after 1
week. b) Discontinuity of CNPase staining in striatum. c) Discontinuity of CNIPase staining in
corpus callosum. d) Normal striatum in the contralateral hemisphere. e) Damaged striatum in
ipsilateral thalamus.
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Figure 3.28. CNPase staining 5 week after PBI (Group 3). a) H&E histology of a PBI lesion after 5
weeks. b) Discontinuity of CNPase staining in the corpus callosum. c) CNPase staining along the
superior edge of a PBI lesion
Figure 3.29. CNPase staining surrounding a collagen scaffold after 1 week (Group 2). a) H&E
histology showing a collagen scaffold in a PBI lesion after 1 week. b) CNPase staining along the
border (white line) of a collagen scaffold at 1 week.
Figure 3.30. CNPase staining at the border of a collagen scaffold after 4 weeks (Group 4). a) H&E
histology of a collagen scaffold in the PBI lesion after 4 weeks. b) CNPase staining near the border
(white line) of a collagen scaffold.
3.3.8 Post-mitotic Neurons: NeuN
1 week after injury, no NeuN positive neurons could be detected within the lesion site
(Figure 3.3 lb). The neuronal loss was found mainly in the striatum, though it extended
to cortical layers in certain areas. After 5 weeks, NeuN positive neurons could be
detected in close proximity to the border of the PBI cavity (Figure 3.32b).
No neurons could be detected in the scaffolds of Group 2 and Group 4. In Group
2, there was a significant area of necrosis separating the areas of NeuN staining from the
scaffold in many places (Figure 3.33b). In Group 4, areas were observed in which
neurons were located closer to the scaffold border (Figure 3.34b).
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Figure 3.31. NeuN staining near the PBI lesion after 1 week (Group 1). a) H&E image of a PBI
lesion after 1 week. b) NeuN staining extending from the border of the PBI lesion into the viable
cortex. There is a complete absence of staining within the lesion.
Figure 3.32. NeuN staining bordering the PBI lesion after 5 weeks (Group 3). a) H&E image of a
PBI lesion after 5 weeks. b) NeuN positive neurons in close proximity to the cavity border.
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Figure 3.33. NeuN staining near a collagen scaffold after 1 week (Group 2). a) H&E image of a
collagen scaffold within a PBI lesion after 1 week. b) Absence of NeuN staining within the collagen
scaffold.
Figure 3.34. NeuN staining bordering a collagen scaffold after 4 weeks (Group 4). a) H&E image of
a collagen scaffold within a PBI lesion after 4 weeks. b) NeuN positive neurons near the edge (white
line) of a collagen scaffold.
3.3.9 Neural Progenitors: Doublecortin
Cells staining positive for Doublecortin were observed in the vicinity of the lesion,
particularly in areas close the lateral ventricles. In Group 1 (Figure 3.35b) and Group 3
(Figure 3.36b), DCX positive cells could be observed in some cases to have migrated
from the subventricular zone to the medial border of the PBI lesion. The proximity of the
lesion site to the subventricular zone seemed to be the main determinant of whether DCX
positive cells were located in the lesion. While DCX positive cells could be also be
found near the lesion sites of Groups 2 and 4, no DCX positive cells were observed
within the collagen scaffolds.
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Figure 3.35. Doublecortin staining near the medial border of a PBI lesion after 1 week (Group 1). a)
H&E image of a PBI lesion after 1 week. b) DCX positive cells spreading from the subventricular
zone to the medial border of the PBI lesion.
Figure 3.36. Doublecortin staining near the medial border of the PBI cavity after 5 weeks (Group 3).
a) H&E image of a PBI lesion after 5 weeks. b) DCX positive cells along the medial border of the
PB! cavity.
3.4 Discussion
Despite the extent of the bilateral penetrating brain injury, the rate of survival among the
rats was relatively good. Following the initial trauma of the injury, the surviving animals
recovered very well and after several days typically displayed no problems with
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ambulating, eating, or grooming. The absence of mortality during or after the scaffold
implantation was important in establishing the safety of the procedure, and also safety of
the implanted material over the time course studied.
Many general characteristics of the lesion 1 week after injury were similar to
those reported for the unilateral frontal injury [40], as would be expected. However,
some differences were also noted beyond what might be expected simply due to the
difference in the anatomical location of the injury. In particular, previous work with the
frontal injury has noted that most necrotic tissue is cleared by one week, leaving the
permanent cavity in the brain. In contrast, we have found that at 1 week in the bilateral
injury, there remains an abundant amount of necrotic tissue still in the process of being
cleared by macrophages. We have found that by 5 weeks, the cavity appears well formed
with most, but not all, debris cleared. In addition, the entire lesion appears to grow
significantly beyond its size at 1 week, with the 5 week lesion being 28% larger. It is
noted that the animals surviving for 5 weeks in Group 3 underwent sham surgery at 1
week, which could have caused additional damage resulting in a larger lesion. Any such
additional injury from the sham surgery was expected to be very small relative to the PBI.
This is supported by previous work comparing the PBI to various surgeries involving
insertion of the probe without inflating the balloon [40]. Minimal injury was found in
those procedures, which themselves were much more severe than the sham surgery we
conducted.
The time course of clearance of necrotic debris and cavity formation is important
in determining the appropriate size for a biomaterial, as well as the time of implantation.
Further, a particular therapeutic agent delivered may only be suitable for implantation at a
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particular time point. For example, certain neuroprotective agents would likely need to
be delivered very shortly after the injury to have maximum efficacy in sparing viable
tissue [124]. However, the use of a biomaterial at an early time point may be precluded
by the lack of space in the lesion, as the permanent cavity has not yet formed. While a
material can be implanted shortly after an injury, it may not fill the cavity after several
weeks in vivo. An early time point also may not be appropriate for cellular therapies,
given that the hemorrhage and cellular debris of the injury environment are cytotoxic
[125].
Implantation at a later time point allows for the cavity to form, and thus for the
biomaterial to fill it. The injury environment may be more hospitable for cellular
therapies or pharmacological agents intended for axonal regeneration. The major
drawback of delayed intervention is that the injury will progress uninhibited during the
period between the injury and the therapy. The potential for limiting the damage of the
injury is thus greatly reduced.
In either case, the possibility for combinatorial therapeutic approaches still exists.
A neuroprotective pharmacological agent could be administered peripherally shortly after
injury, with biomaterial and/or cellular agents delivered surgically at a later time.
In the choice of a biomaterial size, it should be noted that there is a significant
risk of damaging viable tissue if a large material is forced into the brain lesion before a
suitable cavity is available. To address this issue for small and large materials alike, the
mechanical properties of the material should be taken into account. Using a soft material
with characteristics reasonably similar to brain tissue may help to reduce the risk of
damage during implantation. With an appropriate material, one might implant a large,
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but soft, material into a small cavity such that the material will expand to continue to fill
the cavity as it grows larger. We have recently conducted a study of viscoelastic
mechanical properties of collagen scaffolds in order to help in selecting appropriate
scaffolds for future in vivo implantation experiments.
The reactive gliosis observed after the bilateral injury was notable in comparison
to published studies of the unilateral frontal injury. In particular, it has been reported that
GFAP upregulation after PBI peaks around 3 days and returns to a level of very low
reactivity by 7 days [42]. We have found that in the bilateral injury, the reactive gliosis
persists at high levels at 7 days, and appears to be upregulated in both hemispheres even
at 5 weeks post-injury. The increased severity of a bilateral injury relative to the frontal
injury may be a possible explanation for the difference. With a larger volume of tissue
damaged, it is not surprising that the extent of GFAP upregulation may be increased as
the astrocytes surround the injury and isolate it from the rest of the brain. The persistent
upregulation at 5 weeks is somewhat surprising, but is consistent with the timescale
observed for the lesion to progress to a well-defined cavity largely free of necrotic tissue.
The relatively small number of astrocytes detected within the scaffolds is
interesting in that some studies using scaffolds in the brain have reported astrocytes as a
major component of cellular infiltration [126-131]. For example, a study using a gelatin-
siloxane hybrid material reported 5 times as many astrocytes as microglia/macrophages
within the scaffold after 60 days [126]. Implantation of a hyaluronic acid-poly-D-lysine
copolymer hydrogel also resulted in more astrocytes relative to macrophages at time
points of 1, 3, and 6 weeks [127]. However, our study and others indicate a wide
variability in the degree of astrocyte infiltration into materials implanted in the brain [33,
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132-135]. This may be attributable to factors such as the injury model, the implantation
time, the duration of the study, and obviously the material composition of the scaffold.
While many of the studies have used synthetic materials or a combination of natural and
synthetic, one group used a collagen scaffold fairly similar to the one in this study [133].
It was found that a 2% collagen scaffold was surrounded by regions of gliosis after 1
month, but that astrocytes largely did not infiltrate the scaffold. Although we observed a
larger degree of astrocyte infiltration in our work, the predominance of macrophages in
the scaffold relative to astrocytes is consistent between the two studies. It can be
concluded that astrocytes do not seem to have a strong affinity for type I collagen as a
substrate in vivo.
Astrocyte infiltration is of significance in part because it has been suggested that a
scaffold may modify the formation or persistence of a glial scar [33, 127, 128, 134]. By
encouraging astrocytes to move into the lesion and away from the border, one might
prevent organization of the cellular and extracellular matrix barrier that inhibits axonal
regeneration. This reduction of the glial scar would ostensibly facilitate regeneration of
axons and migration of endogenous or exogenous cells to repair the damaged region.
Given the complexity and existing ambiguity of the astrocyte response to injury, such a
presumption is questionable. It has been shown that eliminating the astrocyte response
following injury actually has deleterious, rather than beneficial effects [35, 36, 136].
While reducing gliosis in the long term may in fact reduce inhibitory factors blocking
axonal regeneration, is it not clear whether partially blocking the short-term response of
reactive astrocytes would have therapeutic benefit.
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The ring of CS56 upregulation surrounding the lesion cavity is consistent with
previous reports of the glial scar composition [30, 137]. Cleavage of chondroitin sulfate
proteoglycans remains a target for regenerative therapies, as delivery of chondroitinase
ABC has been shown to allow for increased axon growth after injury [31, 138]. Delivery
of chondroitinase using a collagen scaffold is one such possibility for administration of
therapy.
CD68 staining illustrated the massive macrophage response to the injury after 1
week, along with the decreased, but persistent presence at 5 weeks. In the normal rat
brain, CD68 staining is virtually entirely negative. In the short term after injury, the
macrophage response is likely due to both resident microglia and peripheral monocytes
that enter when the blood-brain barrier loses integrity. Resident perivascular monocytes
in the brain also play a role. At 5 weeks, however, the blood brain barrier has likely been
restored. The presence and distribution of macrophages at this time point suggests that
they may be more likely of microglial origin.
Many of the cells present in the collagen scaffold after 1 week were CD68
positive macrophages. The cells in the scaffold did not appear to be engaging in a
particularly robust foreign body response, as no multinucleated giant cells were detected.
Rather, it may be that the cells were responding to the necrotic debris in and around the
area, which to some degree entered the scaffold. Red blood cells, for example, could be
observed within the scaffold and various macrophages appeared to be phagocytosing
them. The cellular reaction to the scaffolds at 4 weeks was not different in terms of the
density of macrophages. Similar to the case with astrocytes, there is wide variability in
reported macrophage infiltration among previous studies [128, 133]. No authors report
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an explicit absence of macrophages, while nearly all mention the definite or likely
presence of macrophages among the cells within the biomaterials [33, 126-134]. Our
results and previous published studies emphasize that macrophages are likely to respond
to virtually any material implanted into the brain. Macrophages can play a beneficial role
if they a participate in degrading a biomaterial along a desired time frame. Ideally, the
degradation of the material will be accompanied by synthesis of new tissue at a similar
rate. In the brain, this synthesis of new tissue could refer to a deposition of vascularized
extracellular matrix that could serve as a substrate for endogenous or exogenous cells to
repopulate a lesion site. The extent of the macrophage response is also important due to
the complex role that these cells can play in mediating inflammation, survival, and even
regeneration among neural cells. Further, an excessive macrophage response consisting
of uncontrolled proliferation and formation of giant cells can have deleterious effects
[139].
The decrease in degenerating neurons in the thalamus from 1 week to 5 weeks
reflects the stabilization of the lesion. Given that the balloon expanded mostly in the
ipsilateral hemisphere, it is not surprising that most of the degenerating neurons would be
found in the ipsilateral thalamus. The relative lack of positive staining in the
contralateral hemisphere indicates that the damage caused by the probe in the right
hemisphere was small in comparison to the balloon expansion in the left hemisphere.
White matter reactivity in the internal capsule and corpus callosum suggest the possible
presence of axonal damage persisting long term. This is consistent with the fact that
Wallerian degeneration in the CNS occurs much slower that in the peripheral nervous
system [140].
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The pattern of NeuN at 1 week reveals the extent of the injury and begins to
inform about where the lesion ends. Similarly, the areas of CNPase staining at 1 week
give an idea of where the white matter structures have maintained or lost integrity. In
injured or damaged axons, CNPase is one of the first proteins lost. Therefore its presence
1 week after the injury suggests largely viable myelinated axons. At 5 weeks, NeuN and
CNPase staining give a clear picture of how close to the cavity border the viable neurons
and oligodendrocytes localize. In some areas, there appears to be overlap between the
glial scar and CNPase staining. Given that elements of the glial scar are inhibitory for
regenerating axons, it is likely that this white matter is spared rather than regenerated. It
is interesting to note, nonetheless, that the presence of dense GFAP positive regions of
glial scar does not preclude functional axons from traveling through it. It is also
revealing to observe the distortion of normal anatomic organization in response to the
large brain cavity. In particular, areas of the corpus callosum traverse a path that goes
much farther in the superior direction on the left side than that less injured right side.
The lack of NeuN or CNPase positive cells in the scaffold at 1 week is not
surprising. The small scaffold in the middle of the large lesion had little opportunity to
come in contact with viable tissue from which neurons or oligodendrocytes might
migrate. Similarly, at 5 weeks the scaffolds were dwarfed by the size of the lesion and
there would be little chance of a regenerative response taking place in them. While
previous studies have noted some small amounts of staining for neurites and axons within
implanted biomaterials [33, 128, 129, 134, 141], these results do not appear to be
indicative of a robust regenerative response.
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The apparent increase in vascularity surrounding the lesion is consistent with the
infiltration of macrophages and subsequent remodeling to create the PBI cavity.
Although there were only few vessels and/or endothelial cells observed inside the
collagen scaffolds, the numerous vessels surrounding them are an important observation.
In order for a cellular therapy to be successful, there will certainly need to be a vascular
supply present in order for the cells to remain viable for any significant period of time.
With the knowledge that an implanted scaffold will develop vascularity surrounding and
potentially inside it, the delivery of cells becomes a possibility. Based on the time frame
for vascularization, one could potentially implant the scaffold and then deliver the cells
via a targeted injection at a later time. Despite the limited vascularization in this study, It
is also noted that increased vascularization within the scaffold might be possible with a
larger scaffold that better fills the lesion. Studies using other biomaterials have reported
vascularization of the implanted scaffolds when they are in contact with the surrounding
tissue [33, 127-129, 132, 135]. A comparison with the collage scaffold work of Nakada
et al. [133], shows a similar degree of vascularization. Group 4 scaffolds in our work had
2
a density of 4.7 ± 2.1 vessels per mm2 after 4 weeks in vivo, compared with 0.6 ± 0.4 per
mm2 in that study after 1 month. Addition of adipose derived stromal cells in their work
2
resulted in an increased vessel density of 4.6 ± 1.2 per mm
The presence of DCX positive neural progenitors near the lesion site may also be
of benefit in the application of new thereapeutic approaches. While the doublecortin
positive cells were not found in the scaffolds, they were in the vicinity of the injured
areas. In regions of the injury near the subventricular zone, it appeared as though DCX
positive cells migrated towards the lesion. DCX positive cells could be seen along the
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border of the lesion and within the edges of the cavity. The fate of progenitors from the
subventricular zone has been studied in stroke models, where it was revealed that DCX
positive neuroblasts can migrate to the damaged striatum and express markers of medium
spiny neurons [142-144]. While many of these cells undergo apoptosis, some are thought
to survive with functional integration [145]. Cells from the subventricular zone have also
been noted to proliferate and migrate to injured regions followed traumatic brain injury
[146-149]. Although the fate of some subventricular zone cells appears to be astrocyte
differentiation with contribution to glial scarring, it is not clear whether DCX positive
cells are among these [146]. DCX positive cells may have a capacity to replace striatal
neurons as in stroke, but it is unclear whether they could potentially replace lost cortical
neurons [149]. A scaffold delivering a chemoattractant such as stromal derived factor 1
(SDF-1) [150] or stem cell factor (SCF) [151] might improve recruitment of the
progenitors to the lesion site and scaffold.
This work has provided a histological characterization of a bilateral penetrating
brain injury and examined similarities and differences in comparison to published work
with a frontal unilateral injury. The progression of the lesion from 1 week to 5 weeks has
also been described, with a notable increase in the size of the lesion and brain cavity.
This information contributes to an understanding of the pathophysiology of penetrating
brain injury, but also provides guidance in the development of a therapeutic approach
using biomaterials. Based on our initial work implanting a 3 mm diameter collagen
scaffold in the PBI lesion, we have seen that the scaffold must be significantly larger in
order to fill the PBI cavity after several weeks. Further, it is noted that cellular
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infiltration of the scaffolds after 1 week and 5 weeks consists mostly of macrophages,
although astrocytes, and endothelial cells are also present.
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Chapter 4: Treatment of Penetrating Brain Injury in a




Injuries to the brain caused by trauma, cerebrovascular events, and certain
neurodegenerative diseases lead to necrosis and permanent loss of brain parenchyma
[152]. These brain lesions persist in the long term due to intrinsic cellular growth
limitations and extrinsic inhibitory factors in the injury environment that together prevent
robust structural regeneration [1]. Among the most potent of these inhibitory factors are
proteins found in normal myelin which are released as myelinated axons degenerate [153,
154]. The myelin proteins Nogo [155], myelin associated glycoprotein (MAG) [156],
and oligodendrocyte myelin glycoprotein (OMgp) [157] have been identified as major
inhibitory factors in the CNS injury environment which induce acute growth cone
collapse of regenerating axons. It has also been shown that all three proteins bind to
Nogo Receptor 1 (NgG1), initiating cytoskeletal rearrangement through the Rho/ROCK
pathway [158]. A variety of therapeutic strategies have been devised to disrupt this
process following brain and spinal cord injuries including: antibodies against the myelin
proteins and NgR1, siRNA knockdown of NgRl, vaccines against myelin proteins, and
intracellular agents to disrupt the Rho/ROCK pathway [68]. Another approach is the use
of a recombinant soluble Nogo receptor (sNgR) molecule aimed at preventing the myelin
proteins from reaching NgR1 on the cell surface [159]. sNgR has the advantage of
targeting all three myelin proteins simultaneously, while avoiding cytotoxicity and other
problems associated with intracellular agents that much cross the cell membrane.
Additionally, it has recently been shown that the myelin proteins can inhibit axon growth
through the binding of an independent receptor, paired immunoglobulin-like receptor B
(PirB) [23]. Application of sNgR can thus block the effects of the myelin proteins by
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preventing them from reaching cellular NgR1, PirB, or any other unknown receptors for
which they may have affinity. Delivery of sNgR is thus the focus of this study.
In addition to showing efficacy in blocking myelin proteins in vitro, sNgR has
been used in in vivo studies of spinal cord injury and stroke [160-163]. Functional,
electrophysiological, and histological improvements were noted upon administration of
the protein for several weeks.
Unfortunately, therapeutic agents directed at central nervous system pathology
face the obstacle of the blood brain barrier preventing passage of large molecules . One
method for avoiding this issue is to deliver the drug directly to the brain, rather than
administering it peripherally. Some experimental animal studies have used micropumps
to allow for continuous delivery over weeks or months, but this approach is not
convenient for human clinical applications in brain injury. As an alternative, the use of
an implantable biomaterial may provide a feasible method of drug delivery in clinical
scenarios that may already require a neurosurgical procedure. For example, severe
wartime traumatic brain injuries involving penetration of the skull often require
debridement surgery to remove bone and projectile fragments that have entered the brain
[164]. It has also been demonstrated in an animal model the tissue damage extends
beyond the track of the projectile [113, 116]. The major source of injury actually comes
from dissipation of the projectile's kinetic energy, causing a large temporary cavity to
expand within the brain [113]. While the temporary cavity is short-lived, the injury
caused by compression of the surrounding tissue persists. Over time, the area of necrosis
along the projectile path spreads to include the injured surrounding tissue and eventually
the necrotic debris is cleared by macrophages [43]. The resulting cavitary defect remains
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permanently. This cavity may thus afford the possibility of implanting a biomaterial to
fill the defect and deliver a therapeutic agent with the capacity to promote regeneration.
In this study we investigated the implantation of a collagen scaffold in a rat model
of bilateral penetrating brain injury, along with the effects of loading the scaffold with
soluble Nogo receptor. We first sought to evaluate the ability of the scaffold to fill the
defect. Based on our previous work with the injury model, we observed that the lesion
cavity expanded significantly between 1 week and 5 weeks after injury. Implantation of
a scaffold at an early time point is thus complicated by the fact that there is limited space
in the lesion site. However, waiting several weeks until the cavity has fully formed
forgoes the possibility of the therapeutic agent having a beneficial effect on mitigating
the secondary injury process. An implantation time point of 1 week post-injury was thus
chosen in an attempt to satisfy both concerns. In addition to trying to fill the defect, we
studied the interaction of the scaffold with the surrounding brain tissue and identified the
various cell types in and around the scaffold. Similarly, we evaluated whether the
delivery of sNgR could affect the brain-scaffold interaction while potentially mitigating
the injury progression and promoting axonal regeneration.
4.2 Materials and Methods
4.2.1 Experimental Design
3 groups of male Sprague-Dawley rats (n=7) were used in the study, each being
administered a bilateral penetrating brain injury. In the injury model, a balloon-tipped
probe is inserted into the brain and the balloon is rapidly expanded to mimic the
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temporary cavity caused by a projectile. The balloon was inflated to a volume
approximately equal to 10% of the rat brain volume when creating the injury. 1 week
post-injury, animals underwent a second surgery in which they were implanted with
either a collagen scaffold alone (Group 5), or a scaffold loaded with sNgR (Group 6 and
Group 7). Group 5 and 6 were sacrificed 4 weeks after scaffold implantation (5 weeks
post-injury), while Group 7 was sacrificed 8 weeks after scaffold implantation (9 weeks
post-injury). The experimental groups are summarized in Table 3.
Table 3. Experimental Groups
Group 5 (n=7) Group 6 (n=7) Group 7 (n=7)
1 't surgery Injury without Injury without Injury without
intervention intervention intervention
2 n surgery Implantation of Implantation of Implantation of
collagen scaffold collagen collagen
scaffold loaded scaffold loaded
with sNgR with sNgR
Sacrifice time 5 weeks 5 weeks 9 weeks
(post-injury)
4.2.2 Penetrating Brain Injury Apparatus
The PBI model was developed at the Walter Reed Army Institute of Research and has
been used in several published studies to date [40, 42, 43, 120, 122, 165-170]. The model
aims to simulate damage to the brain caused by a projectile by mimicking both the
destruction of tissue along the projectile path, as well as the temporary cavity formed by
dissipation of the projectile's kinetic energy. The injury is created by inserting a probe
into the brain, which has a balloon attached near the tip. With the probe inserted, a
pneumatic device creates a pressure impulse to rapidly inflate and deflate the balloon
within the brain. The result of the balloon expansion is to compress the surrounding
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tissue, similar to the action of the temporary cavity in a ballistic injury. Although the
model does not recreate certain features of the clinical injury, such as retained bone
fragments or subsequent infectious processes, it is useful for studying other
characteristics of the injury and for creation of a standardized cavitary defect in the brain.
4.2.3 Collagen Scaffold Fabrication and sNgR Loading
Type I collagen scaffolds (1.0% weight:volume) were fabricated from medical grade
porcine microfibrillar collagen (Geistlich Biomaterials, Wolhusen, Switzerland). A
suspension of the collagen was made in 0.001 N HCl, brought to pH 3, and mixed for 20
minutes. The slurry was blended at 15,000 RPM (Ultra Turrax T18 blender, IKA,
Staufen, Germany) for 30 minutes at 4' C, brought again to pH 3, and blended for an
additional 2 hours. The slurry was then centrifuged for 10 minutes at 5500 RPM to
remove bubbles, and mixed with a pipette to ensure homogeneity. The slurry was poured
in a metal mold and placed into an AdVantage Benchtop Freeze Dryer (VirTis, Gardiner,
NY). The temperature was decreased at a controlled rate to -40' C over 180 minutes and
held at -40' C for 60 minutes. Sublimation was conducted at 0' C and a pressure of 200
mTorr for 1020 minutes. Scaffolds were then dehydrothermally cross-linked overnight at
105' C under vacuum. Published work using similar scaffolds has determined the pore
size to be approximately 100-150 [tm.
The scaffolds in Group 1 were chemically cross-linked using 1-ethyl-3-(3-
dimethylaminopropryl)carbodiimide hydrochloride (EDC) (Sigma-Aldrich Inc, St. Louis,
MO) with addition of N-hydroxysuccinimide (NHS) to increase the reaction rate. An
EDC:NHS ratio of 5:2 was used, and the scaffolds were cross-linked for 1 hour at room
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temperature. EDC cross-links collagen through activation of carboxylic acid groups that
react with lysine free amine groups to form amide bonds. EDC is a water soluble agent
that does not remain in the collagen after the scaffolds have been thoroughly rinsed. This
is advantageous for in vivo applications due to the fact that many cross-linking agents
such as glutaraldehyde are cytotoxic. Following cross-linking, the scaffolds were freeze-
dried again, soaked for 2 hours in PBS, and freeze-dried a final time. The scaffolds were
eventually cut into the desired implant size with a 4 mm diameter biopsy punch. The
scaffolds in the dry state were approximately 4 mm in diameter and 2 mm thick, but after
full hydration measured approximately 6 mm in diameter and 3 mm in thickness.
Scaffolds in Group 2 were chemically cross-linked in the same manner, except
that they were first soaked for two hours in a 1.0 mg/mL solution of sNgR. The cross-
linking was expected to immobilize a small mount of sNgR on the scaffold by covalent
linkage. This would provide for a some release of sNgR in the event that the scaffold
degraded in vivo over time. In actuality, the scaffolds were not degraded in vivo, and any
cross-linked sNgR was unlikely to have a significant effect. Following cross-linking, the
scaffolds were freeze-dried, and then soaked in an 8.2 mg/mL sNgR solution. The
scaffolds loaded with the sNgR solution were freeze-dried a final time and cut to the
desired size for implantation.
4.2.4 Soluble Nogo Receptor
The soluble Nogo receptor is a fusion protein produced by Biogen Idec. It is developed
by fusing cDNA encoding the 1st 310 amino acids of rat NgR1 with cDNA encoding the
Fc region of rat IgGI, followed by expression in Chinese hamster ovary cells [161]. The
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resulting protein consists of the rat IgGI Fc region with two NgR molecules replacing the
IgGI antigen binding fragment.
4.2.5 Surgical Procedure and Animal Care
27 male Sprague-Dawley rats were used in this study. All procedures were approved by
the Boston VA Healthcare System Institutional Animal Care and Use Committee.
Animals were shaved, anesthetized with isoflurane, and positioned in a stereotaxic
frame where the anesthetic delivery was maintained through a nosecone. A circulating
water heating pad was used to maintain body temperature throughout the surgery and also
for several hours during the post-operative recovery. Heart rate and blood oxygen
saturation were monitored from a probe on the foot during the procedure.
After sterilizing the skin with 13% povidone iodine solution, a midline incision
was made along the top of the head to expose the skull, followed by a lateral incision
extending from the posterior aspect of the midline incision and passing just anterior to the
left ear. With the top of the skull and the left side of the head exposed, a portion of the
left temporalis muscle was excised with care taken to avoid damaging the temporal
branch of the facial nerve. With the lateral aspect of the skull exposed, a 3 mm diameter
window was drilled in the skull at a position 1 mm anterior to bregma and 3 mm ventral
to bregma.
The PBI probe was inserted into the brain, with the tip advanced 10 mm from the
surface of the left hemisphere into the right hemisphere. The PBI balloon was inflated to
a diameter of 6.3 mm to create an injury encompassing approximately 10% of the rat
brain volume. It is noted that the balloon is several mm proximal to the tip of the probe,
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such that the balloon inflation is predominately in the left hemisphere despite the probe
tip being in the right hemisphere. This scenario mimics a projectile entering the left
hemisphere and dissipating its kinetic energy before coming to rest in the right
hemisphere. Following the balloon inflation, the probe was retracted from the brain and
bleeding was controlled using Gelfoam. The cranial window was covered with a Bio-
Gide collagen membrane (Geistlich Biomaterials, Wolhusen, Switzerland) and the
surgical incision was closed with a 4-0 suture.
1 week after the injury, animals underwent a second surgery in which a second
incision was made parallel to the lateral incision from the first surgery, enabling access to
the defect site. After removing the collagen membrane covering the cranial window, the
lesion site was exposed. In Group 5, the collagen scaffolds were hydrated with 25 uL
PBS immediately prior to implantation into the defect. In Group 6 and Group 7, the
scaffolds were hydrated with 25 uL of 8.26 mg/mL sNgR solution before implantation.
The scaffold were implanted very shortly after hydration, such that the scaffolds had not
yet expanded to their full size. The delivered dose was estimated to be between 200 and
300 ug. The cranial window in each case was covered again with a collagen membrane
and the incision closed with a 5-0 suture.
Following all surgeries, animals were allowed to recover in warmed cages with
additional oxygen and food and water provided at bedding level. Buprenorphine (0.05
mg/kg) was given for pain relief, while Cefazolin (20 mg/kg) was given to prevent
infection.
4.2.6 Animal Sacrifice and Specimen Processing
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Animals were sacrificed 4 weeks (Groups 5 and 6) or 8 weeks (Group 7) after the
implantation of the collagen scaffolds. Before sacrifice, animals were deeply
anesthetized with an intraperitoneal injection of sodium pentobarbital (150 mg/kg).
Animals were then transcardially perfused with 150 mL cold heparanized PBS (20
units/mL) followed by 250 mL cold 4% paraformaldehyde solution (USB corporation
19943, Cleveland, OH.) Brains were extracted and immersed in 4% paraformaldehyde
for 2-3 days at 4' C. Brains were processed through reagent alcohol (70% - 10 min, 80%
- 90 min, 95% - 2 x 90 min, 100% - 2 x 90 min, 100% - 90 min under vacuum), xylene (3
x 90 min), and paraffin (2 x 180 min under vacuum, 58 C). Samples were then
embedded in paraffin and sectioned on a mictrome at 5 im. Sections were taken at
approximately 1 mm intervals spanning the lesion. Slides were dried on a warmer at 60'
C for several hours.
4.2.7 Histology and Immunohistochemistry
Sections were stained with hematoxylin and eosin for histomorphometric analysis and for
general histologic observation of the injury.
The fluorescent dye Fluoro-Jade C (Millipore AG325) was used for visualization
of degenerating neurons in the thalamus. Sections from approximately 2.5 mm posterior
to bregma were deparrafinized and rehydrated prior to incubation in 0.06% KMnO4
(Sigma 223468) for 20 minutes. After 3 rinses in deionized water, slides were then
stained with 0.00015% Fluoro-Jade C solution for 20 minutes and rinsed 3 more times in
water. Slides were dried on a warmer at 60' C for 10 minutes, placed in xylene for
several minutes, and coverslipped with Cytoseal mounting medium.
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Antibodies, dilution factors, and antigen retrieval methods used for
immunohistochemistry are summarized in Table 4. The staining procedure was
conducted at room temperature. Following deparrafization, rehydration, and antigen
retrieval, slides were rinsed with wash buffer (Dako S3006) containing TBS and 0.05%
Tween 20. Slides were blocked for 2 hours with Dako protein block (Dako X0909) prior
to addition of the primary antibody for 2 hours. Following 3 rinses with wash buffer, the
secondary antibody was added for 1 hour. After 3 more rinses, a 100 ng/mL solution of
the fluorescent DNA stain 4',6-diamidino-2-phenylindole (DAPI) was added for 30
minutes. 3 final rinses with wash buffer were performed and the slides were then placed
in TBS for 3 minutes. The slides were transferred to a 0.1% solution of Sudan Black
(Sigma 199664) dye for 20 minutes in to reduce tissue autofluorescence. Following 3
rinses in TBS, slides were coverslipped with Immu-mount aqueous mounting medium
(Thermo Scientific 9990402).
Table 4 Immunohistochemistry reagents (Abbreviations: rb (rabbit), ms (mouse), gt (goat)
1 Antibody Source Retrieval Dilution 2' Antibody
GFAP (rabbit Dako 0.1% Protease 1:500 Dylight 488 donkey




Von Willebrand Dako 0.1% Protease 1:100 Dylight 488 donkey
Factor (rabbit (A0082) XIV 40 min anti-rabbit IgG
polyclonal) (Sigma P5147) (Jackson
ImmunoResearch 711-
485-152)
Doublecortin Santa Cruz Citrate buffer pH 1:100 Dylight 488 donkey
(goat (sc-8066) 6, 2 min 120' C anti-goat IgG (Jackson
polyclonal) (Dako S 1699) ImmunoResearch 705-
485-003)
CD68 (mouse Serotec 0.1% Protease 1:200 Dylight 549 donkey
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monoclonal (MCA341R) XIV 20 min anti-mouse IgG
IgG) (Sigma P5147) (Jackson
ImmunoResearch 715-
505-150)
NeuN (mouse Millipore Citrate buffer pH 1:200 Dylight 549 donkey
monoclonal (MAB 377) 6, 1 min 1200 C anti-mouse IgG
IgG) (Dako S 1699) (Jackson
ImmunoResearch 715-
505-150)
CNPase (mouse Abcam Citrate buffer pH 1:500 Dylight 549 donkey
monoclonal (ab6319) 6, 20 min 950 C anti-mouse IgG
IgG) (Dako S 1699) (Jackson
ImmunoResearch 715-
505-150)
CS56 (mouse Sigma 0.1% Protease 1:100 Rhodamine donkey
monoclonal (C8035) XIV 40 min anti-mouse IgM
IgM) (Sigma P5147) (Jackson
ImmunoResearch 715-
025-020)
Neurofilament Abcam None 1:150 Dylight 549 donkey




Tau- 1 (mouse Millipore Citrate buffer pH Prediluted Dylight 549 donkey
monoclonal (IHCR1O15- 6, 2 min 120' C anti-mouse IgG
IgG) 6) (Dako S 1699) (Jackson
ImmunoResearch 715-
505-150)
MAP lb (mouse Abcam Citrate buffer pH 1:100 Dylight 488 donkey





Light microscope images were taken with an Olympus camera interfaced with a Olympus
BX51 microscope, while fluorescent images were captured an Olympus DP71 camera
interfaced with an Olympus BX60 microscope. Adobe Photoshop CS3 was used for
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minor image processing procedures such as cropping and adjustment of levels to reduce
background.
4.2.9 Histomorphometric Analysis and Cell Counts
Lesion area was demarcated in hematoxylin and eosin stained sections at approximately 1
mm intervals spanning the lesion. The lesion was defmed by areas of obvious necrosis
with lack of cellularity, along with regions of dense macrophage infiltration, hemorrhage,
gliosis, and vacuolization. A linear interpolation was used to reconstruct an approximate
volume, with the volume between sections being equal to the average of the areas
multiplied by the distance between them. Cell density was determined by counting the
number of cells within the scaffold and normalizing by diving by the scaffold area.
4.2.10 Statistics
Numerical values are reported at mean I standard error, and all statistical analysis was
performed using Statview (version 5.0.01, SAS Institute Inc., Cary, NC). Unpaired t-
tests were used to compare differences between experimental groups, with a p-value of
0.05 used for determining statistical significance.
4.3 Results
4.3.1 Animal Survival, Recovery, and Qualitative Behavioral Observations
22 out of 27 animals survived, with all deaths occurring after the first surgery. No
obvious differences were noted in the animal recovery or behavior in the three groups.
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Similarly, the response to the injury was generally the same as has been observed in
previous work. In particular, the rats had right forelimb deficits that improved several
days after the injury. It is noted that all of the animals survived the implantation of the
scaffold at 1 week post-injury and appeared not to suffer any deleterious effects from it.
This establishes that implantation of large scaffolds 1 week after the injury is technically
feasible in the rat model and is safe for the animals over several weeks. Animals
generally lost weight over the first 2 days after the injury before resuming weight gain.
Following the implantation surgery, animals generally maintained their weight
(Figure 4.1, Figure 4.2, and Figure 4.3).
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Figure 4.1. Group 5 Weight Progression Following PBI and Scaffold Implantation
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Figure 4.2. Group 6 Weight Progression Following PBI and Scaffold Implantation
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Figure 4.3. Group 7 Weight Progression Following PBI and Scaffold Implantation
4.3.2 Lesion Volume and Scaffold-Brain Histological Observations
The volume of the lesion in Group 5 was found to be 84.2 ± 5.2 mm 3, while the lesion in
Groups 6 and 7 were 72.8 ± 5.3 mm3 and 93.8 ± 11.2 mm3 , respectively. The lesion in
Group 7 was significantly larger than in Group 6 (p=0.009), but was not significantly
different from Group 5 (Figure 4.4). Group 5 and Group 6 were not significantly
different.









Figure 4.4. Lesion Volume for Groups 5, 6, and 7. Lesion volume in Group 7 was significantly larger
than that of Group 6 (p=0.009).
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Scaffolds in Group 5 appeared to mostly fill the lesion, with some cellular
infiltration (Figure 4.5). The scaffold pores remained open, and no signs of degradation
were evident. Scaffolds in Group 6 similarly filled the lesion, but appeared to be much
more integrated with the surrounding tissue (Figure 4.6). One could find in some cases a
dense cellular infiltrate with deposition of extracellular matrix inside the scaffold.
Additionally, cells of varying morphology could be seen, suggesting the infiltrate was not
restricted to a single cell type (Figure 4.6c). Among the visible cells were what appear to
be numerous macrophages, including several multinucleated giant cells. Endothelial cells
lining small blood vessels were apparent within the scaffolds of Group 6 based. Other
phenotypes possible for such cells with elongated nuclei include microglia, endothelial
cells, or less likely fibroblasts. Group 5 scaffolds had some cells with similar
morphology, but few foreign body giant cells were observed. Additionally, very little
extracellular matrix could be detected within the Group 5 scaffold in comparison to
Group 6. Group 7 scaffolds were qualitatively similar to those of Group 6, with some
samples showing a robust infiltration of cells (Figure 4.7). The Group 7 scaffolds
appeared to be intact and undegraded.
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Figure 4.5. H&E Histology 4 Weeks after Scaffold Implantation (Group 5). a) H&E image showing
a scaffold filling the defect in Group 5, 4 weeks after implantation. b) Cellular infiltration at the
inferior border of the scaffold. c) Sparse cellular infiltration near the superior medial border of the
lesion cavity.
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Figure 4.6. H&E Histology 4 Weeks after Implantation of an sNgR-loaded Scaffold (Group 6). a)
H&E image of the PBI lesion with an sNgR loaded scaffold filling the defect. The cellular infiltrate
can be seen even at low magnification. b) Dense cellular infiltration near the medial border of the




Figure 4.7. H&E Histology 8 Weeks after Implantation of an sNgR-loaded Scaffold (Group 7). a)
H&E image of a PBI lesion with an sNgR scaffold filling much of the defect 8 weeks after
implantation. b) Dense cellular infiltrate near the superior border of the lesion. c) Cellular
infiltrate near the inferior border of the scaffold.
4.3.3 Glial Scarring and Inflammation: GFAP and CD68
Intense GFAP staining was observed surrounding the lesion boundary in Groups
5, 6, and 7. A transition was observed in astrocyte morphology when moving closer to
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the lesion. The normal astrocytes showed distinct processes and the typical star-like
morphology. However, closer to the lesion the astrocyte processes were no longer
distinct, and instead stained as a nearly uniform band. The amount of GFAP staining
within the scaffolds was generally low relative to the surrounding tissue (Figure 4.8,
Figure 4.9, and Figure 4.10.
Figure 4.8. GFAP Staining Near the Implanted Scaffold after 4 weeks (Group 5). a) H&E image of
a PBI lesion with an implanted scaffold. b) GFAP staining surrounding the scaffold, with some
scattered staining within the scaffold.
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Figure 4.9. GFAP Staining Near an sNgR-loaded Scaffold after 4 weeks (Group 6). a) H&E image
of an sNgR loaded scaffold within a PBI lesion. b) Dense GFAP staining surrounding the scaffold,
with a little staining within the scaffold
Figure 4.10. GFAP Staining Near an sNgR-loaded scaffold after 8 weeks (Group 7). a) H&E image
of an sNgR scaffold with a PBI lesion. b) GFAP staining surrounding the scaffold, with a some
staining also seen within the scaffold.
The density of astrocytes within the collagen scaffolds was found to be 9.2 +2.1,
10.7 ± 2.9, and 30.1 ± 4.5 cells/mm2 for Groups 5, 6, and 7, respectively. The astrocyte
density in Group 7 was significantly greater that that in Group 5 and 6 (p=0.001 and
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p=0.004, respectively), while Groups 5 and 6 were not significantly different
(Figure 4.11).














Figure 4.11. GFAP cell density within collagen scaffolds (Groups 5, 6, 7). GFAP cell density in
Group 7 scaffolds was significantly higher than in Group 5 (p=0.001) and Group 6 (p=0.00 4 ).
The cellular infiltration of the scaffold appeared to consist predominantly of
macrophages in most cases. Many CD68-positive macrophages were observed around
the lesion and within the scaffolds of all groups (Figure 4.12, Figure 4.13, Figure 4.14).
135
...............  . .................... .......... ................................. . . ............ 
.
Figure 4.12. CD68-positive macrophages within a collagen scaffold after 4 weeks (Group 5). a) 20x
magnification image showing numerous macrophages within a scaffold. b) High magnification
image showing a macrophage along a scaffold strut. (Red: CD68, Blue: DAPI)
Figure 4.13. CD68-positive macrophages within an sNgR-loaded scaffold after 4 weeks (Group 6). a)
20x magnification image showing a very dense macrophage infiltrate within a scaffold. b) 40x image
showing macrophages among cells of other phenotypes within the scaffold. (Red: CD68, Blue: DAPI)
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Figure 4.14. CD68 positive macrophages within an sNgR-loaded scaffold after 8 weeks (Group 7). a)
H&E image of a scaffold within a PBI lesion. b) Macrophages within the scaffold.
The density of CD68-positive macrophages within the collagen scaffolds was 27.6 ± 6.3,
218.7 ± 51.9, and 57.0 ± 7.0 cells/mm 2 for Groups 5, 6, and 7, respectively (Figure 4.15).
The Group 6 density was significantly higher than that of both Group 5 and 7 (p=0.003
and p=0.009, respectively). The Group 7 density was also significantly higher than that of
Group 5 (p=0.009).










Figure 4.15. CD68 Cell Density Within Collagen Scaffolds (Groups 5, 6, and 7). Group 6 had a
significantly higher density of macrophages in the scaffold than Group 5 (p=O.003) and Group 7
(p=0.009). Group 7 also had a higher density than Group 5 (p=0.009).
4.3.4 Fluorojade C Staining for Degenerating Neurons
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By 5 weeks and 8 weeks post-injury, very few fluorojade-positive neurons could be
detected in the thalamus or cortex. There was, however, persistent white matter reactivity
in the corpus callosum, external capsule, and internal capsule.
4.3.5 Von Willebrand Factor Staining for Endothelial Cells
Numerous blood vessels were observed surrounding the lesion, including both small
capillaries and some larger vessels. A few blood vessels were detected within the
scaffolds of Group 5 (Figure 4.16), while considerably more were seen in Group 6
(Figure 4.17) and Group 7 (Figure 4.18) scaffolds. An average density of 6.1 + 1.1
vessels/mm 2 were counted in Group 5 scaffolds (Figure 4.19), which was significantly
less than the 26.1 ± 4.5 vessels/mm2 in Group 6 (p=0.001) and 15.9 ± 3.4 vessels/mm2 in
Group 7 (p=O.018).
Figure 4.16. VWF positive cells/vessels in a collagen scaffold after 4 weeks (Group 5). a) VWF




Figure 4.17. VWF positive cells/vessels in a sNgR loaded scaffold after 4 weeks (Group 6). a) H&E
image of a scaffold within a PBI lesion. b) VWF positive cells/vessels distributed throughout the
collagen scaffold (white line indicates approximate scaffold border). c) 40x magnification of VWF
positive cells/vessels. (Green: VWF, Blue: DAPI)
Figure 4.18. VWF positive cells/vessels in a sNgR loaded scaffold after 8 weeks (Group 7). a) VWF
positive cells/vessels within a collagen scaffold. b) Additional VWF positive cells/vessels with a
scaffold.
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Figure 4.19. VWF Cell/Vessel Density within collagen scaffolds. The density of cells/vessels in Group
6 and Group 7 was significantly greater than in Group 5 (p=0.001 and p=0.018, respectively).
4.3.6 CNPase Staining for Oligodendrocytes
CNPase staining revealed myelinated axons of the corpus callosum and internal capsule
near the lesion site. CNPase oligodendrocytes could be observed near the edge of the
scaffolds in each group and occasionally they were seen in contact with scaffolds
(Figure 4.20, Figure 4.21, and Figure 4.22. Oligodendrocytes were not, however, found
at distances within the scaffolds beyond 100-200 pm.
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Figure 4.20. CNPase staining near the border of a collagen scaffold after 4 weeks (Group 5). a)
DAPI stain showing cells in close proximity or in contact with a collagen scaffold (white lines show
scaffold struts). b) A CNPase positive oligodendrocyte (white arrow) slightly within the border of
the scaffold.
Figure 4.21. CNPase staining near the border of an sNgR loaded scaffold after 4 weeks (Group 6). a)
DAPI staining showing cells within the scaffold, near its border. White lines indicate scaffold struts.
b) CNPase positive oligodendrocytes (white arrows) slightly within the scaffold border.
Figure 4.22. CNPase staining near the border of an sNgR loaded scaffold after 8 weeks (Group 7). a)
CNPase staining showing myelinated axons near the scaffold border (white line) b) CNPase staining
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showing myelinated axons and a few oligodendrocytes (white arrows) in contact with the scaffold
edge
4.3.7 NeuN Staining for Mature Neurons
NeuN-positive neurons were found surrounding the lesion site and in close proximity to
the scaffold. In each group, isolated areas could be identified in which neurons were
within the scaffold borders (Figure 4.23, Figure 4.24, and Figure 4.25). In some cases,
neurons could be observed directly in contact with the scaffold struts. Similar to the
distribution of oligodendrocytes, neurons were not observed deep within the scaffolds.
Figure 4.23. NeuN staining near the border of a collagen scaffold after 4 weeks (Group 5). a) NeuN
positive neurons in viable brain near the scaffold edge. White lines indicate the approximate location
of scaffold struts b) A few NeuN positive cells (white arrow) within the scaffold
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Figure 4.24. NeuN staining near the border of an sNgR loaded scaffold after 4 weeks (Group 6). a)
DAPI staining showing cells slightly within the scaffold border. Scaffold struts are indicated with
white lines b) NeuN staining showing a few neurons (white arrows) within the scaffold.
Figure 4.25. NeuN staining near the border of an sNgR loaded scaffold after 8 weeks (Group 7). a)
NeuN staining showing a few neurons within the scaffold, near the superior border. White lines
indicate scaffold struts b) 40 x magnification of the neurons (white arrows), surrounded by scaffold
struts.
4.3.8 Doublecortin Staining for Neural Progenitors
Cells staining positive for DCX were found in the subventricular zone and subgranular
zone of the dentate gyrus, similar to what one would find in uninjured brain. In sections
where the lesion was in proximity to the subventricular zone, DCX positive cells
appeared to have migrated to areas surrounding the lesion. It appeared possible that the
cells may have proliferated relative to the staining seen in normal brains. While some
DCX positive cells were occasionally found close to the scaffolds, no such cells were
observed within the scaffolds of either group.
4.3.9 Tau-1, Neurofilament, and MAP1b Staining for Axons
Antibody staining for markers Tau-1, Neurofilament, and MAP lb revealed axons
generally coursing around the lesion, often in close proximity to the borders of collagen
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scaffolds. The pattern of Neurofilament staining was similar among the three groups,
with an absence of axon staining at significant distances within the scaffold. While axons
may have contacted the edge of the scaffold in some cases, they mostly traversed outside
of the border along lesion periphery (Figure 4.26, Figure 4.27, and Figure 4.28).
Figure 4.26. Neurofilament staining bordering a collagen scaffold after 4 weeks (Group 5). a) DAPI
staining showing cells along and within the scaffold border (white line). b) Neurofilament staining of
axons running alongside the scaffold, but not within it.
Figure 4.27. Neurofilament staining bordering an sNgR loaded scaffold after 4 weeks (Group 6). a)
DAPI staining showing cells bordering the scaffold and a dense infiltrate into the scaffold. b)
Neurofilament staining along the scaffold border, but not within the scaffold.
144
........  ....... .......... . . . . -- I - I
Figure 4.28. Neurofilament staining bordering an sNgR loaded scaffold after 8 weeks (Group 7). a)
DAPI staining showing cells along and within the scaffold border (white line). b) Neurofilament
staining showing axons passing adjacent to the scaffold.
Staining for Tau- 1 was somewhat similar to neurofilament, but showed more staining of
axons in gray matter. Many oligodendrocytes were also found to stain positive for Tau-1,
which has been reported previously [171-175]. Tau-l positive staining generally
bordered the scaffold (Figure 4.29), but in isolated cases was seen to encroach slightly
within the scaffold margins (Figure 4.30 and Figure 4.31).
Figure 4.29. Tau-1 staining bordering a collagen scaffold after 4 weeks (Group 5). a) DAPI staining
showing cells bordering and within the scaffold. The white line indicates the scaffold border. b)
Tau-1 staining showing axons bordering the scaffold, but not entering it.
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Figure 4.30. Tau-1 staining near the border of an sNgR loaded scaffold after 4 weeks (Group 6). a)
DAPI staining showing cells near the scaffold border and slightly within it. White lines indicate
scaffold struts. b) Tau-1 staining which comes in contact with the scaffold near the lesion border.
Figure 4.31. Tau-1 staining near the border of an sNgR loaded scaffold after 8 weeks (Group 7). a)
DAPI staining showing a dense cellular infiltrate into the collagen scaffold. The scaffold border is
indicated by the white line. b) Tau-1 staining showing axons in contact with the scaffold border, but
not extending far within the scaffold.
4.4 Discussion
The procedure for preparing and implanting the collagen scaffolds resulted in the lesion
cavities being mostly filled several weeks after implantation. Knowledge of the
approximate size of the defect after 1 week, and later after 5 weeks allowed for a
reasonably appropriate choice of scaffold size. While there are areas for improvement to
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ensure that viable tissue is not injured during the implantation, several principles can be
taken away from this study and previous work to plan future experiments with the PBI
model. First, previous work implanting dry scaffolds seemed to have produced
variability in terms of the amount of bleeding induced and the final volume of the lesion
after 4 weeks. Here, we have taken the approach of hydrating the scaffold prior to
implantation, resulting in a softer material of stiffness similar to that of the brain. For
scaffolds loaded with protein or having undergone multiple freeze-drying cycles,
hydration is also crucial for expanding the material and opening the pores. The timing of
this expansion is of importance due to the limited size of the cranial window through
which the material is implanted. A fully expanded scaffold of 6 mm diameter is
considerably larger than the cranial window, which measures only 3-4 mm. By hydrating
the scaffold immediately prior to implantation, the scaffold can be inserted through the
window before it has fully expanded. The scaffold is thus easier to insert, but will
expand in vivo to come in contact with the border of the cavity. By designing the
scaffold to have mechanical properties reasonably similar to brain, it can safely rest
within the tissue in a slightly compressed state after the initial implantation.
Additionally, it appears from our observations that the scaffold will continue to expand as
the lesion cavity grows over several weeks. The size of the scaffold should thus be
carefully chosen, as a scaffold that is too large may cause tissue damage, while an
undersized scaffold will fail to fill the defect. The scaffolds used in Group 5 may have
been slightly too large, as the size of the lesion was somewhat greater than in lesions
without scaffold implantation. It is noted that the implantation procedure can be
simplified by increasing the size of the cranial window. While this is an option, we
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considered it preferable to minimize the size of the craniotomy in light of the severity of
the injury to be administered in the animals. One can also consider the use of injectable
materials that solidify or gel after being introduced into the brain [176-179]. They have
the advantage of conforming to the shape of the cavity, but are limited in terms of
controlling pore size, a critical factor for cellular infiltration.
The difference in cellular infiltration between Group 5 and the sNgR groups
indicates an effect of the soluble Nogo receptor, but the nature of the histological
response appears somewhat complex in light of the supporting immunohistochemistry.
The pattern of GFAP staining suggests that the neither the scaffold, nor the sNgR, have
an effect on the glial scar. The dense gliosis surrounding the lesion was also notable in
that it generally did not extend to within the scaffold, though we did observe more
astrocytes after 8 weeks relative to 4 weeks. Previous studies have reported that scaffolds
of varying composition seem to promote astocyte infiltration [130, 135], with potential
disruption of the glial scar [134]. Given that the densities of GFAP positive cells was
relativelylow, it appears that astrocytes do not have a strong affinity for migrating into
collagen scaffolds in vivo. This is consistent with our previous results using smaller
scaffolds, although the degree of cellular infiltration was less in those cases. The lack of
astrocytes within the scaffolds in this study was somewhat surprising in consideration of
the fact that multiple other cell types were present. While astrocytes are a source of
chondroitin sulfate proteoglycans that contribute to the glial scar [180, 181], it appears
that the dense extracellular matrix within the scaffolds in Group 6 was not deposited by
astrocytes. Rather, it is likely that the macrophages/microglia within the scaffolds were
responsible for the extracellular matrix.
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The CD68 positive macrophages were the most common cell type identified in the
scaffolds of all groups. This is an expected result due to the persistence of the
biomaterial at 5 weeks, as virtually any implant will elicit some degree of a foreign body
reaction. There was a difference, however, in that the scaffolds containing sNgR had
more macrophages in them and also displayed more multinucleated giant cells. There are
a number of possible explanations for these observations. First, it is possible that the
sNgR molecule itself was recognized as being foreign, thus stimulating an immune
response to eliminate it. This seems unlikely due to the fact that the NgR molecule and
the Fc region it is fused to are both of rat origin. Further, the sNgR molecule has been
used in a number of other studies without evidence of an immune response. However,
the presence of the Fc region itself might be the initiator of the immune response due to
complement binding. Another possibility is that the amount of protein delivered, rather
than the identity of protein, promoted a macrophage response. In contrast to other studies
that delivered continuous small doses of sNgR over long time periods, the implanted
scaffold contained the entire dose of sNgR. The introduction of several hundred
micrograms of protein at once might have induced a macrophage response, possibly
through binding of complement. It is possible that sNgR with bound myelin proteins
might also promote complement binding and a subsequent macrophage infiltration to
clear the complexes. The presence of the multinucleated giant cells throughout the
scaffold suggests that perhaps the cross-linking procedure in the sNgR group affected the
antigenicity of the scaffolds. This would imply that the sNgR cross-linked to the scaffold
enhanced the foreign body response to the material. This, however, also seems unlikely
due to the small amount of sNgR that could be cross-linked and the fact that the cross-
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linked sNgR would not be appreciably different from the free sNgR loaded in the
scaffold. While the cross-linking might disrupt certain epitopes of the protein, there is no
particular reason to believe that this would affect the response by macrophages. If the
cross-linked sNgR had bound and immobilized myeling proteins, complement binding
might then induce a macrophage response directed against the scaffold-sNgR-myelin
complex. A simpler explanation would be that the presence of the protein simply
increased the degree of cross-linking of the scaffold. A more highly cross-linked scaffold
might thus be more likely to induce a robust foreign body reaction. It has been shown
that the addition of the lysine amino acid increases the stability of collagen cross-linked
by carbodiimide treatment [182] . This explanation potentially falls short due to the fact
that the cross-linking procedure in Group 1 was expected to rather thoroughly cross-link
the collagen even in the absence of an additional protein. Based on previous work, one
would expect a high degree of cross-linking after a 1 hour reaction with an EDC:NHS
ratio of 5:2 [96]. Thus, any additional cross-linking due to the sNgR would be unlikely to
change the chemical structure of scaffold to a large extent.
A somewhat intriguing idea relates to recent discoveries that some macrophages
actually express the Nogo receptor [183-186]. In one study examining clearance of
macrophages from peripheral nerve injuries, it was found that the presence of myelin
seemed to promote macrophage efflux from the injury site [184]. Blocking the action of
myelin proteins via NgR knockouts, siRNA knockdowns of NgR, or intracellular
Rho/ROCK inhibition reversed the effect and resulted in macrophages persisting in the
lesion site. It was suggested that similar effects might be present in the central nervous
system such that myelin proteins act as repulsive agents to keep macrophages from
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spreading beyond the injury site and also act as a cue for macrophage efflux as the
inflammatory response dies down [183]. As a result, it was hypothesized that blocking
NgR signaling might result in the persistence of macrophages at CNS lesion sites. It is
noted, however, that in such a scenario there must be a balance between myelin proteins
instructing macrophages to migrate away and the presence of necrotic debris with
cytokines etc. telling macrophages to migrate towards the injury. The distinction
between myelin proteins within a necrotic region of the CNS that must be cleared, and
those within intact axonal myelin causing macrophage clearance is not clear. While
further study would be required to elucidate the mechanism, it does appear that the
delivered sNgR had some effect on promoting macrophage infiltration of the scaffolds.
The increased macrophage density in Group 6 relative to Group 7 does not have an
obvious explanation, but it could simply be the result of variation in the animals groups
and scaffold preparation.
The presence of significant vascularity within the scaffolds of Groups 6 and 7
provides a potential framework for future regenerative therapies. Untreated defects of
this kind typically result in a large cavity, free of any cellular or extracellular matrix
components. In order for any regeneration to take place, the void must be filled with a
physical substrate for cell and axon growth, but also must have a source of oxygen for
cell survival. By demonstrating the formation of vessels throughout a portion of the
scaffold filling the defect, the possibility for survival of endogenous or transplanted
neural cells is greatly enhanced. While the infiltrating cells in the scaffold are clearly
viable, one can foresee a therapy in which exogenous cells might be delivered to the
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lesion site after allowing a sufficient time for vacularization and extracellular matrix
formation within a scaffold.
Given that Group 5 had fewer vessels within the boundary of the scaffolds, the
sNgR receptor appears to have had an indirect effect on vascular proliferation. It appears
likely that the increase in macrophage infiltration in Groups 5 and 6 also served to
increase recruitment of endothelial cells for vessel formation. Further, the extracellular
matrix deposited by the macrophages was likely important for small vessel formation due
to the relatively large pore size of the scaffolds. Macrophages and endothelial cells
infiltrating have been observed to infiltrate biomaterials implanted in the brain in other
studies [33, 126, 129, 132].
The isolated areas in which neurons and oligodendrocytes were observed within
the scaffold border are likely not indicative of any significant regenerative response.
Rather, these areas demonstrate that there the collagen scaffold can integrate with viable
brain tissue in particular areas. This may be related to variability in the glial scarring,
making some regions more conducive to interaction of neurons and oligodendrocytes
with the biomaterial. The sNgR molecule was intended as a therapy to bind myelin
proteins in the injury site, thus permitting an increased degree of axonal regeneration. If
regenerating axons did indeed infiltrate into the scaffold, it would be reasonable to
assume that oligodendrocyte might also migrate to the lesion to myelinate the axons.
However, we were unable to observe significant ingrowth of axons into the scaffold
beyond isolated peripheral areas. A smaller injury with a smaller scaffold would be
helpful in better understanding whether the areas of tissue integration we have observed
may have any therapeutic potential. In future work, antibody staining for GAP-43 may
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also be of benefit for visualizing axons that may be regenerating even if they are not in
the scaffold.
The role of the macrophages in and around the scaffold may be both beneficial
and harmful for regeneration. Given that the scaffold does not appear to degrade
significantly over a period of several weeks, it is possible that it could remain
indefinitely. Whether or not this might have major deleterious effects is unknown. If a
proliferation of giant cells persists to a greater extent, it could be harmful and lead to a
loss of viable tissue [139]. Clearly, this would not be an appropriate environment for
regeneration of axons and migration of neurons. Macrophages have, however, been
shown to have beneficial effects in regeneration after optic nerve lesions [187]. The
effects of inflammatory processes involving macrophages and their interactions with
other cell types is a topic of considerable complexity. With regard to this work, it can be
concluded that the presence of macrophages in the scaffold seems to have correlated with
increased vascularity of the lesion site. The fact that a very large cavity can potentially
be vascularized seems to be a positive development. Development of a more degradable
scaffold might allow for vascularization and ECM deposition, but with an eventual
resolution of the macrophage response. The lesion site might then present a more
suitable environment for regenerative therapies.
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Chapter 5: Implantation of a Collagen Scaffold Seeded
with Adult Rat Hippocampal Progenitors in a Rat Model
of Penetrating Brain Injury
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5.1 Introduction
Pre-clinical studies of stem/progenitor cell therapies have shown promise for a number of
central nervous system injuries and diseases [55, 57, 188-195]. The unique
characteristics of each pathology guide the various decisions that must be made for
designing an appropriate therapeutic strategy. Some of the considerations that must be
taken into account include the goal of the therapy (e.g. neuroprotection vs. regeneration),
the cell type to be used, the environmental conditions affecting survival, proliferation,
and differentiation in vitro and in vivo, the medium for delivering the cells, the desired
anatomical location for engraftment, and the timing and surgical procedure for
administering the therapy. Many of these factors are not independent, and compromises
must inevitably be made in choosing how to proceed.
Penetrating brain injury, commonly encountered in military conflicts due to
bullets and shrapnel, represents a somewhat complicated case for cellular therapies. The
injury is characterized by tissue destruction along the trajectory of the projectile, as well
as damage to surrounding areas from the formation of a temporary cavity. The temporary
cavity results from dissipation of the projectile's kinetic energy as it tumbles through the
tissue, and may commonly be many times larger than the diameter of the projectile [39].
A combination of mechanical damage, along with hemorrhage, ischemia, and cytotoxic
molecular elements, leads to a complex and often severe injury. A rat model of PBI has
been developed recently that reproduces several aspects of the clinical injury without the
use of actual projectile. The model involves insertion of balloon-tipped probe into the
brain, followed by a rapid inflation of the balloon to mimic the temporary cavity seen in a
ballistic injury [40]. While not reproducing all aspects of clinical PBI (e.g. infection and
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retained fragments in the brain), this model serves as a useful tool for studying
implantation of potential cellular therapies into a standardized cavitary defect.
The goals for treatment of PBI may include both neuroprotection to mitigate the
extensive secondary injury, and also regeneration to replace lost neurons and glial cells.
The extent to which both goals might be achieved with the same cell population remains
to be elucidated as the field moves forward, but current research indicates that all
available cell sources have significant limitations that would make a single cell therapy
inadequate. Rather, a particular cell type might be suitable for addressing some of the
elements of the larger problem, while a combination of delivered cell types might be
necessary for a more complete therapy. In PBI, several different regions of the brain may
be affected, each with a variety of different cell types and subtypes. An attempt at
replacing or rebuilding part of a lost brain structure would likely require a comprehensive
multifactorial approach targeting inflammation, cytotoxic elements, inhibitory factors,
growth states of endogenous cells, implantation of large numbers of exogenous
replacement cells, and appropriate control mechanisms for differentiation and anatomical
localization for the delivered cells.
Addressing the multitude of obstacles that prevent full regeneration after brain
injury remains a goal for the future. At present, we focus on a few important features of
PBI in consideration of how cellular therapy might be of potential benefit. The injury
environment immediately after PBI is likely to be highly inhospitable for implanted cells.
Hemoglobin and glutamate toxicity, along with ionic imbalances and regions of ischemia
are likely to kill exogenous and endogenous cells alike [41]. It would logically be
advantageous from a cell-survival standpoint to wait until the acute phase of the injury
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has resolved before performing an implantation. We have thus chosen for this study to
wait 1 week after injury before delivering cells to the injury site.
While neural progenitor cells of varying origin have been implanted in traumatic
brain lesions [177, 178, 196-215], we have chosen to use a population of adult
hippocampal neural progenitors [216, 217]. The cells have been demonstrated to survive
and differentiate into neurons, astrocytes, and oligodendrocytes both in vitro and in vivo
when implanted into the uninjured brain [216]. Further, in vitro experiments have
demonstrated that the cells can differentiate into neurons with various neurotransmitter
phenotypes [218]. This particular population of cells, which has been well-characterized
[216-223], does not appear to have been previously implanted in a model of traumatic
brain injury. In this work, we have evaluated the survival and differentiation of these
cells in the rat model of PBI.
The histological response to PBI involves the eventual clearance of necrotic
debris, resulting in the formation of a large cavity in the brain. This cavity, surrounded
by a glial scar, remains unfilled and essentially precludes the possibility of any significant
regeneration within the lesion. Filling the cavity with a biomaterial can provide
mechanical continuity across the lesion, while also serving as a delivery vehicle for cells.
In this work, we implanted a pre-formed collagen scaffold seeded with BrdU-labeled
undifferentiated neural progenitors. Survival and differentiation were then analysized
with immunohistochemical methods.
5.2 Materials and Methods
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5.2.1 Experimental Design
6 male Sprague-Dawley rats underwent a bilateral penetrating brain injury involving
insertion of a balloon-tipped probe, followed by inflation of the PBI balloon to a volume
approximately equal to 10% of that of the rat brain. 1 week later, the animals underwent
a second surgery in which they were implanted with a collagen scaffold seeded with
BrdU-labeled adult hippocampal neural progenitors. Animals were sacrificed 4 weeks
later (5 weeks post-injury).
5.2.2 Penetrating Brain Injury Apparatus
The PBI model was developed at the Walter Reed Army Institute of Research and has
been used in several published studies to date [40, 42, 43, 122]. The model aims to
simulate damage to the brain caused by a projectile by mimicking both the destruction of
tissue along the projectile path, as well as the temporary cavity formed by dissipation of
the projectile's kinetic energy. The injury is created by inserting a probe into the brain,
which has a balloon attached near the tip. With the probe inserted, a pneumatic device
creates a pressure impulse to rapidly inflate and deflate the balloon within the brain. The
result of the balloon expansion is to compress the surrounding tissue, similar to the action
of the temporary cavity in a ballistic injury. Although the model does not recreate certain
features of the clinical injury, such as retained bone fragments or subsequent infectious
processes, it is useful for studying other characteristics of the injury and for creation of a
standardized cavitary defect in the brain.
5.2.3 Collagen Scaffold Fabrication
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Type I collagen scaffolds (1.0% weight:volume) were fabricated from medical grade
porcine microfibrillar collagen (Geistlich Biomaterials, Wolhusen, Switzerland). A
suspension of the collagen was made in 0.001 N HCl, brought to pH 3, and mixed for 20
minutes. The slurry was blended at 15,000 RPM (Ultra Turrax T18 blender, IKA,
Staufen, Germany) for 30 minutes at 4' C, brought again to pH 3, and blended for an
additional 2 hours. The slurry was then centrifuged for 10 minutes at 5500 RPM to
remove bubbles, and mixed with a pipette to ensure homogeneity. The slurry was poured
in a metal mold and placed into an AdVantage Benchtop Freeze Dryer (VirTis, Gardiner,
NY). The temperature was decreased at a controlled rate to -40' C over 180 minutes and
held at -40' C for 60 minutes. Sublimation was conducted at 0' C and a pressure of 200
mTorr for 1020 minutes. Scaffolds were then dehydrothermally sterilized and cross-
linked overnight at 1050 C under vacuum. Published work using similar scaffolds has
determined the pore size to be approximately 100-150 tm.
5.2.4 Cell Culture and Scaffold Seeding of Adult Hippocampal Neural
Progenitors
T-150 cell culture flasks were coated overnight with 10 pg/mL poly-L-ornithine, rinsed
twice with sterile water, and coated again overnight with 5 ug/mL mouse laminin.
Frozen cells were thawed and plated at a density of approximately 10,000 cells/cm 2 . The
cells were plated and expanded in DMEM/F12 high glucose medium containing L-
glutamine, 1% penicillin, 1% streptomycin, 1% N2 supplement, and 20 ng/mL FGF-2.
The medium was changed every 2-3 days. At the time of the first medium change, 2.5
ptM BrdU was added and maintained throughout the culture period. On the morning of
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the implantation surgery the cells were detached using Accutase, counted, and
resuspended in medium at a density of approximately 20 million cells/mL.
Collagen scaffolds approximately 6 mm in diameter and 3 mm in thickness were
placed in a 96-well plate to immobilize them for cell-seeding. A total of 60 tL of the cell
suspension was pipetted onto the scaffold in each well in 3 increments of 20 pL. The 6
mm scaffolds were larger than desired for implantation, so a 4 mm biopsy punch was
used to obtain the desired 4 mm scaffolds. The number of cells in the 4 mm diameter
scaffolds was not known precisely, but was estimated to be around 4-5 million based on
the density of the cell suspension and the volume of the scaffold. After seeding, the
scaffolds were kept in an incubator until the time of surgical implantation.
5.2.5 Surgical Procedure and Animal Care
6 male Sprague-Dawley rats were used in this study. All procedures were approved by
the Boston VA Healthcare System Institutional Animal Care and Use Committee.
Animals were shaved, anesthetized with isoflurane, and positioned in a stereotaxic
frame where the anesthetic delivery was maintained through a nosecone. A circulating
water heating pad was used to maintain body temperature throughout the surgery and also
for several hours during the post-operative recovery. Heart rate and blood oxygen
saturation were monitored from a probe on the foot during the procedure.
After sterilizing the skin with 13% povidone iodine solution, a midline incision
was made along the top of the head to expose the skull, followed by a lateral incision
extending from the posterior aspect of the midline incision and passing just anterior to the
left ear. With the top of the skull and the left side of the head exposed, a portion of the
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left temporalis muscle was excised with care taken to avoid damaging the temporal
branch of the facial nerve. With the lateral aspect of the skull exposed, a 3 mm diameter
window was drilled in the skull at a position 1 mm anterior to bregma and 3 mm ventral
to bregma.
The PBI probe was inserted into the brain, with the tip advanced 10 mm from the
surface of the left hemisphere into the right hemisphere. The PBI balloon was inflated to
a diameter of 6.3 mm to create an injury encompassing approximately 10% of the rat
brain volume. It is noted that the balloon is several mm proximal to the tip of the probe,
such that the balloon inflation is predominately in the left hemisphere despite the probe
tip being in the right hemisphere. This scenario mimics a projectile entering the left
hemisphere and dissipating its kinetic energy before coming to rest in the right
hemisphere. Following the balloon inflation, the probe was retracted from the brain and
bleeding was controlled using Gelfoam. The cranial window was covered with a Bio-
Gide collagen membrane (Geistlich Biomaterials, Wolhusen, Switzerland) and the
surgical incision was closed with a 4-0 suture.
1 week after the injury, animals underwent a second surgery in which a second
incision was made parallel to the lateral incision from the first surgery, enabling access to
the defect site. After removing the collagen membrane covering the cranial window, the
lesion site was exposed. A cell-seeded collagen scaffold was then implanted into the
lesion site. The cranial window was covered again with a collagen membrane and the
incision closed with a 5-0 suture.
Following all surgeries, animals were allowed to recover in warmed cages with
additional oxygen and food and water provided at bedding level. Buprenorphine (0.05
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mg/kg) was given for pain relief, while Cefazolin (20 mg/kg) was given to prevent
infection.
5.2.6 Animal Sacrifice and Specimen Processing
Animals were sacrificed 4 weeks after the implantation of the collagen scaffolds (5 weeks
post-injury). Before sacrifice, animals were deeply anesthetized with an intraperitoneal
injection of sodium pentobarbital (150 mg/kg). Animals were then transcardially
perfused with 150 mL cold heparanized PBS (20 units/mL) followed by 250 mL cold 4%
paraformaldehyde solution (USB corporation 19943, Cleveland, OH.) Brains were
extracted and immersed in 4% paraformaldehyde for 2-3 days at 4' C. Brains were
processed through reagent alcohol (70% - 10 min, 80% - 90 min, 95% - 2 x 90 min,
100% - 2 x 90 min, 100% - 90 min under vacuum), xylene (3 x 90 min), and paraffm (2 x
180 min under vacuum, 58 C). Samples were then embedded in paraffin and sectioned
on a mictrome at 5 tm. Sections were taken at approximately 1 mm intervals spanning
the lesion. Slides were dried on a warmer at 60' C for several hours.
5.2.7 Histology and Immunohistochemistry
Sections were stained with hematoxylin and eosin for histomorphometric analysis and for
general histologic observation of the injury.
The fluorescent dye Fluoro-Jade C (Millipore AG325) was used for visualization
of degenerating neurons near the lesion and remotely in the thalamus. Sections from
approximately 1 mm anterior to bregma and 2.5 mm posterior bregma were
deparrafinized and rehydrated prior to incubation in 0.06% KMnO 4 (Sigma 223468) for
162
20 minutes. After 3 rinses in deionized water, slides were then stained with 0.00015%
Fluoro-Jade C solution for 20 minutes and rinsed 3 more times in water. Slides were
dried on a warmer at 60' C for 10 minutes, placed in xylene for several minutes, and
coverslipped with Cytoseal mounting medium.
Antibodies, dilution factors, and antigen retrieval methods used for
immunohistochemistry without BrdU staining are summarized in Table 4. The staining
procedure was conducted at room temperature. Following deparrafization, rehydration,
and antigen retrieval, slides were rinsed with wash buffer (Dako S3006) containing TBS
and 0.05% Tween 20. Slides were blocked for 2 hours with Dako protein block (Dako
X0909) prior to addition of the primary antibody for 2 hours. Following 3 rinses with
wash buffer, the secondary antibody was added for 1 hour. After 3 more rinses, a 100
ng/mL solution of the fluorescent DNA stain 4',6-diamidino-2-phenylindole (DAPI) was
added for 30 minutes. 3 final rinses with wash buffer were performed and the slides were
then placed in TBS for 3 minutes. The slides were transferred to a 0.1% solution of
Sudan Black (Sigma 199664) dye for 20 minutes in to reduce tissue autofluorescence.
Following 3 rinses in TBS, slides were coverslipped with Immu-mount aqueous
mounting medium (Thermo Scientific 9990402).
For BrdU double-labeling, the slides underwent antigen retrieval in citrate buffer
at 1200 for 1 min, but for GFAP and CD68 staining there was no protease treatment. Von
Willebrand factor slides had additional protease treatment for 20 minutes. It was
observed that the protease treatment caused degradation of the scaffolds, and thus most of
the cells observed were in the surrounding brain tissue. For the BrdU staining, 10%
donkey serum was used for the blocking step, while the Dako wash buffer was used to
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dilute the antibodies. Reagents containing bovine serum albumin were avoided due to
potential cross-reactivity of bovine IgG with the anti-goat secondary antibody. Double
labeling was conducted sequentially, rather than simultaneously.
Table 5 Immunohistochemistry reagents (Abbreviations: rb (rabbit), ms (mouse), gt (goat)
10 Antibody Source Retrieval Dilution 20 Antibody
GFAP (rabbit Dako 0.1% Protease 1:500 Dylight 488 donkey
polyclonal) (Z0334) XIV 25 min anti-rabbit IgG (Jackson
(Sigma P5147) ImmunoResearch 711-
485-152)
Von Willebrand Dako 0.1% Protease 1:100 Dylight 488 donkey
Factor (rabbit (A0082) XIV 40 min anti-rabbit IgG (Jackson
polyclonal) (Sigma P5147) ImmunoResearch 711-
485-152)
Doublecortin Santa Cruz Citrate buffer pH 1:100 Dylight 488 donkey
(goat (sc-8066) 6, 2 min 120' C anti-goat IgG (Jackson
polyclonal) (Dako S 1699) ImmunoResearch 705-
485-003)
CD68 (mouse Serotec 0.1% Protease 1:200 Dylight 549 donkey
monoclonal (MCA341R) XIV 20 min anti-mouse IgG
IgG) (Sigma P5147) (Jackson
ImmunoResearch 715-
505-150)
NeuN (mouse Millipore Citrate buffer pH 1:200 Dylight 549 donkey
monoclonal (MAB 377) 6, 1 min 1200 C anti-mouse IgG
IgG) (Dako S 1699) (Jackson
ImmunoResearch 715-
505-150)
MAP lb (mouse Abcam Citrate buffer pH 1:100 Dylight 488 donkey
monoclonal (ab3095) 6, 1 min 1200 C anti-mouse IgG
IgG) (Dako S 1699) (Jackson
ImmunoResearch 715-
485-150)
CNPase (mouse Abcam Citrate buffer pH 1:500 Dylight 549 donkey
monoclonal (ab6319) 6, 20 min 950 C anti-mouse IgG
IgG) (Dako S 1699) (Jackson
ImmunoResearch 715-
505-150)
BrdU (sheep Abcam Citrate buffer pH 1:200 Dylight 549 donkey
polyclonal) (abl893) 6, 1 min 120 C anti-sheep IgG (Jackson




Light microscope images were taken with an Olympus camera interfaced with a Olympus
BX51 microscope, while fluorescent images were captured an Olympus DP71 camera
interfaced with an Olympus BX60 microscope. Adobe Photoshop CS3 was used for
minor image processing procedures such as cropping and adjustment of levels to reduce
background.
5.2.9 Histomorphometric Analysis and Cell Counts
Lesion area was demarcated in hematoxylin and eosin stained sections at approximately 1
mm intervals spanning the lesion. The lesion was defined by areas of obvious necrosis
with lack of cellularity, along with regions of dense macrophage infiltration, hemorrhage,
gliosis, and vacuolization. A linear interpolation was used to reconstruct an approximate
volume, with the volume between sections being equal to the average of the areas
multiplied by the distance between them. Cell density was determined by counting the
number of cells within the scaffold and normalizing by diving by the scaffold area.
5.2.10 Statistics
Numerical values are reported as mean ± standard error, and all statistical analysis was
performed using Statview (version 5.0.01, SAS Institute Inc., Cary, NC). Unpaired t-
tests were used to compare differences between experimental groups, with a p-value of
0.05 used for determining statistical significance.
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5.3 Results
5.3.1 Animal Survival, Recovery, and Qualitative Behavioral Observation
Qualitatively, the animals in this work did not show obvious behavioral differences
relative to our previous work. Similar to other groups, there was some weight loss over
the first couple days after the injury which was subsequently regained (Figure 5.1). The
rats had a deficit in their right forelimb during the first few days after injury, which was
notable mainly when they were grasping food. The weakness and/or lack of coordination
improved over the first week such that they eventually were able to grasp food normally
with both forelimbs. It is possible that minor improvements in forelimb function might
have been present as a result of implanted cells, but sensitive behavioral tests would have
been necessary for detection. We do note that the animals appeared to suffer no
deleterious effects as a result of the implanted cells. All animals undergoing the
implantation procedure recovered without problems and survived the duration of the
study.
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Figure 5.1. PBI Weight Progression for Group 8. Animals typically lost weight for 1-2 days after the
injury, but thereafter resumed weight gain. Weight was generally maintained following the 2 nd
surgery to implant the cell-seeded scaffold.
5.3.2 Lesion Volume and Scaffold-Brain Histological Observations
Histology revealed that the lesion consisted of very large cavity, similar to that
seen in previous studies after 5 weeks. The average volume of the entire lesion was
found to be 58.0 +6.7 mm 3. The implanted scaffolds were present and structurally intact,
but did not fill the entire cavity (Figure 5.2a). There appeared to be areas of integration
between the scaffold and surrounding brain tissue, typically near the lateral aspect of the
lesion (Figure 5.2b). Cells of heterogeneous morphology were present bordering and
within the scaffolds (Figure 5.2c).
167
Figure 5.2. H&E Histology of a Scaffold Seeded with Neural Progenitors (Group 8). a) H&E image
of a scaffold within the lesion site 4 weeks after implantation. b) Integration of the scaffold with
tissue a the lateral edge of the brain. c) Cellular infiltration of the scaffold.
5.3.3 Implanted Cell-Seeded Scaffolds
At the time of seeding the collagen scaffolds for surgical implantation, additional
scaffolds were seeded and processed for immunohistochemical evaluation. It was desired
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to verify in vitro the status of the cells as being BrdU-labeled and predominantly
undifferentiated. Antibody staining confirmed that nearly all of the cells were BrdU
positive (Figure 5.3), while many were Nestin positive (Figure 5.4). Very few cells were
GFAP positive (Figure 5.5). No positive staining could be detected for CNPase, NeuN,
MAPib, VWF, and CD68.
Figure 5.3. Collagen scaffold containing BrdU labeled neural progenitors (prior to implantation). a)
DAPI staining showing the nuclei of cells within the scaffold. b) BrdU staining showing that nearly
all of the cells within the scaffold were labeled with BrdU.
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Figure 5.4. Collagen scaffold containing nestin-positive neural progenitors (prior to implantation).
a) 1Ox magnification image showing many cells staining positive for nestin within the scaffold. b)
20x image showing a cluster of cells with most staining positive for nestin. c) 40x image of nestin
positive cells along a scaffold strut. (Green: Nestin, Blue: DAPI)
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Figure 5.5. Collagen scaffold containing a GFAP positive cell (prior to implantation). a) 20x image
demonstrating that very few cells in the scaffold were GFAP positive. b) 40x image of a GFAP
positive cell. (Green: GFAP, Blue: DAPI)
5.3.4 Survival of Implanted Neural Progenitors
Despite the large lesion and the undersized scaffold, implanted neural progenitors were
detected in brains from all of animals. The BrdU staining revealed that some of the cells
had remained in the scaffold, while others had migrated into the surrounding brain tissue
(Figure 5.6). BrdU labeled cells could be detected several hundred micrometers from the
scaffold border, and were restricted in all cases to the ipsilateral hemisphere.
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Figure 5.6. BrdU labeled neural progenitors detected in vivo 4 weeks after implantation. a) H&E
image of a scaffold within the PBI lesion 4 weeks after implantation. b) DAPI staining (blue)
showing nuclei of cells at the scaffold border (white line) and within the brain on the medial side. c)
BrdU staining (red) showing implanted cells that have survived in the brain after 4 weeks.
5.3.5 Glial Scarring and Inflammation: GFAP and CD68 Staining
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The typical pattern of glial scarring was observed around the lesion in the form of
upregulated GFAP expression. Areas of gliosis diminished with increasing distance from
the lesion, but appeared to be upregulated throughout much of the left hemisphere. A
small amount of GFAP staining was present within the collagen scaffolds, though the
majority of cells were negative. A number of BrdU labeled cells in the surrounding brain
tissue were also found to be GFAP positive. BrdU-positive astrocytes could be detected
within areas of glial scarring (Figure 5.7a) in all of the samples. In at least 4 samples,
BrdU-positive astrocytes could also be found within areas of normal-appearing brain
(Figure 5.7b).
Figure 5.7. Implanted neural progenitors staining positive for BrdU and GFAP after 4 weeks. a)
Double labeling for DAPI (blue) and GFAP (green) showing that some implanted cells differentiate
into astrocytes (arrow) among the glial scar bordering the scaffold. b) Double labeling showing
implanted cells that differentiate into astrocytes (arrows) in normal appearing brain tissue.
CD68 staining revealed the presence of many macrophages in and around the lesion site,
as well as in both ipsilateral and contralateral white matter tracts. Many of the cells
around and within the scaffold were CD68 positive. In at least 5 of the samples, CD68
positive macrophages in the brain which also appeared to stain positive for BrdU could
be detected (Figure 5.8).
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Figure 5.8. Implanted neural progenitors staining positively for CD68. a) Double labeling for BrdU
(blue) and CD68 (red) showing an implanted cell (arrow) that may have differentiated into a
macrophage within the brain. b). An implanted cell (arrow) from a different animal staining
positively for BrdU (blue) and CD68 (red).
5.3.6 Von Willebrand Factor Staining: Blood Vessels and Endothelial Cells
Numerous blood vessels were present surrounding the lesion and in some cases around
the periphery of the scaffold. Vessels were generally not found to a significant degree
within the scaffold. In all samples, small vessels could be identified in the surrounding
brain which included BrdU-positive endothelial cells (Figure 5.9).
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Figure 5.9. Implanted neural progenitors staining positively for VWF. a) DAPI staining (magenta)
showing nuclei of all cells in the field. b) BrdU staining (blue) showing implanted cells. c) Double
labeling for BrdU (blue) and VWF (green) showing a small blood vessel with three implanted cells
(white arrows) that have taken on an endothelial cell phenotype.
5.3.7 CNPase Staining for Oligodendrocytes
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CNPase staining revealed the presence of oligodendrocytes and myelinated axons in the
vicinity of the lesion, and in some cases directly bordering the cavity. CNPase positive
cells were not observed within the collagen scaffold, though there were oligodendrocytes
present near the scaffold interface with surrounding brain. In all samples, cells were
identified which stained positively for CNPase and BrdU. The BrdU labeled
oligodendrocytes were sometimes found within regions of denser CNPase staining
around clusters of other oligodendrocytes (Figure 5.10). Perineuronal oligodendrocytes
were also observed near neuronal cell bodies (Figure 5.11).
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Figure 5.10. Implanted neural progenitors staining positive for CN]Pase. a) DAPI staining
(magenta) showing nuclei of all cells in the field. b) CNPase staining (green) showing several
oligodendrocytes. c) Double labeling for BrdU (blue) and CNPase (green) showing three implanted
cells (arrows) that have differentiated into oligodendrocytes.
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Figure 5.11. Implanted neural progenitor differentiated into a perineuronal satellite
oligodendrocyte. a) DAPI staining (magenta) showing nuclei of all cells in the field. b) CNPase
staining (green) showing a perineuronal satellite oligodendrocyte (white arrow). c) Double labeling
for BrdU (blue) and CNPase (green) showing that the perineuronal satellite oligodendrocyte is an
implanted cell.
5.3.8 NeuN Staining for Mature Neurons
178
.................. ................. :::::N:: . U : z :: : :- -::: .. =1:1 111111 .  .-I :::: ....... ...... . ................... .A " , , - --- I - ........... ...... ............. :::::::  - : : :
While mature neurons were found in the viable brain tissue surrounding the lesion, no
NeuN-positive neurons were observed within the scaffold. Very few BrdU positive cells
also stained for NeuN (Figure 5.12).
Figure 5.12. Implanted neural progenitor staining positive for NeuN. a) DAPI staining (magenta)
showing nuclei of all cells in the field. b) NeuN staining (red) showing post-mitotic neurons. c)
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Double labeling for BrdU (blue) and NeuN (red) showing an implanted cell (arrow) that appears to
stain dimly, but positively, for NeuN.
5.3.9 MAP1b Staining for Neurons
The MAPIb did not stain cell bodies specifically enough to identify cells which might be
both BrdU and MAPlb positive.
5.3.10 Doublecortin staining for Neural Progenitors
While doublecortin positive cells could be seen in and around the subventricular zone, no
DCX positive cells were found in or immediately around the scaffold. Due to the lack of
positive DCX cells, double-labeling was not conducted.
5.4 Discussion
The survival and recovery of the animals following the injury and the subsequent
implantation surgery establishes the safety of these methods for future studies. We
observed no adverse behavioral effects as a result of the implanted cells, and there were
no tumors or irregular cell growths seen on histology. While electrophysiology
measurements were not made, we did not observe any seizures or severe neurological
abnormalities beyond the expected forelimb deficits.
Many different cell types have been used previously in studies of traumatic brain
injury, including marrow derived stromal cells [224], adipose derived stromal cells [133],
umbilical cord blood derived cells [225], post-mitotic neurons [208], and fetal and adult
stem/progenitor cells [226]. Cell therapies have in some cases shown beneficial effects
on functional recovery and lesion volume [205, 226]. However, the adult rat
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hippocampal progenitors used in this study have not, to our knowledge, been used
previously in models of traumatic brain injury or stroke.
The basic characteristics of the PBI cavity were similar to those of other groups,
with most of the necrotic debris cleared by 5 weeks post-injury. The cavity in the brain
expanded to a degree which made the implanted biomaterial somewhat undersized. A
large portion of the scaffold's surface area was not in contact with the surrounding brain,
but rather was simply suspended in the lesion cavity. A smaller injury would be
advantageous for future work since greater proximity of the scaffold with the brain would
allow more of the implanted cells to migrate out into the surrounding tissue. Similarly,
one may expect more integration of endogenous cells with both the scaffold and the
delivered neural progenitors. Although the average lesion volume was less than the
average for injured animals without implanted scaffold, the difference was not
statistically significant.
While many of neural progenitor cells survived, the 1 week time point for
implantation presented some challenges. In particular, the surgical procedure involved a
significant amount of bleeding due to the scar tissue that formed around the cranial
window. Although it appeared that much of the bleeding was external to the skull, it was
nonetheless difficult to implant the scaffold without exposing the material and cells to
some bleeding. One potential solution would be to wait an additional week in order to
allow for further stabilization of the vasculature both in the scar outside the skull and
within the evolving brain lesion. A slightly larger cranial window may also provide the
opportunity for more precise localization of the scaffold with minimization of bleeding.
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The cellularity of the scaffolds appeared to consist of a combination of the
exogenous implanted neural progenitors and endogenous cells that migrated into the
scaffold. Despite lack of chemical cross-linking, the scaffolds did not appear to be
degrading. Whether or not the scaffold might remain in vivo indefinitely is not clear, but
the lack of a robust foreign body response suggests that it might maintain structural
integrity for a period of least months.
The GFAP reactivity surrounding the lesion suggests formation of a glial scar
typical for this kind of lesion. The intense staining all along the border of the cavity
indicates that neither the scaffold nor the cells had a notable effect on disrupting the glial
scar. Other studies have described astrocyte infiltration of scaffolds [130] and reduction
in gliosis around the lesion[134]. In our work with collagen scaffolds, we have not
observed any such effect. This would imply that the material composition of the scaffold
is of importance for determining which cell types are likely to migrate into it. It is also
not a foregone conclusion that astrocyte infiltration is a beneficial scenario, particularly if
the astrocytes are of a reactive phenotype and aren't accompanied by other cell types. In
this work, we did observe a relatively small number of astrocytes within the scaffold. In
some cases, these appeared to be implanted progenitors that differentiated into astrocytes.
Previous work has shown that stem/progenitor cells implanted into lesion sites sometimes
preferentially differentiate into astrocytes. This may be a result of the same factors in the
injury environment that produce gliosis among endogenous astrocytes. Although we
observed progenitors that have differentiated into astrocytes, we have also observed
differentiation into various other cell types. We conclude from this that the 1 week time
point for implantation may be beneficial in limiting the degree of astrocyte differentiation
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and allowing for differentiation into other phenotypes. After 1 week, the resolution of the
acute phase of the injury may result in an environment with fewer inflammatory
mediating factors [204], thus permitting the more diverse differentiation.
Macrophages observed throughout the scaffold appeared to be the most abundant
cell type. Their infiltration of the scaffold was likely due in part to erythrocytes and other
dead cells that accumulate during and after the implantation. While collagen is a natural
material, the presence of virtually any implant stimulates macrophages to some extent. It
is also noted that type I collagen is not normally found in the brain [227], which may
enhance the reaction of macrophages and microglia. The observed response was not a
particularly robust foreign body reaction, based on the lack of multinucleated giant cells
and the fact that the interface between brain and scaffold is not particularly dense with
macrophages. Interestingly, several macrophages appeared to also stain positively for
BrdU. The simplest explanation for this observation would be that the macrophages
phagocytosed some of the dead implanted progenitors. It may also be possible that cell
fusion resulted in transfer of DNA from the BrdU labeled cells to endogenous
macrophages [228]. It is noted in some cases that the BrdU staining was in a dense, well-
circumscribed pattern than colocalized with the cell nucleus under visualization of the
DAPI stain. This is in contrast to other double-labeled macrophages in which the BrdU
staining was more disorganized and fragmented, suggesting that another cell has been
phagocytosed. While it initially seems unlikely that this population of hippocampal
neural progenitors would have the capability to differentiate into microglia with a
macrophage phenotype, the possibility cannot be ruled out. Although microglia and
macrophages are of mesodermal origin, it has been shown that mouse neural progenitors
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can differentiate into endothelial cells [229], which also are generally of mesodermal
origin. Careful in vitro experiments would be needed to establish whether or not the
apparent differentiation of these neural progenitors into microglia/macrophages is a real
effect.
The pattern of degeneration in the thalamus and white matter tracts was similar to
that seen in previous studies. The timing of implantation may have precluded the
possibility of a significant neuroprotective effect, as we have observed that by 5 weeks
the number of neuronal cell bodies staining positively is low. It appears that perhaps
most of the neurons die within the first week, so that an implantation time of 1 week is
simply too late to have an effect. With earlier implantation and evaluation time points, it
may still be worth investigating whether a neuroprotective effect might be observed
[230].
The vascularization surrounding the lesion is consistent with observations from
previous groups of animals. The presence of BrdU labeled cells among the blood vessel
endothelial cells is an interesting finding with significant therapeutic potential. It is first
acknowledged that some double-labeled endothelial cells could have been the result of
fusion between implanted and endogenous cells. While we cannot definitively rule out
this possibility, it has been conclusively demonstrated that mouse neural progenitor cells
can differentiate into endothelial cells in vitro and in vivo [229]. It would be reasonable
to expect that cells of rat origin might possess the same capability, indicating that the
observed cells likely did differentiate in vivo. Previous work demonstrated that the
presence of endothelial cells stimulated the endothelial differentiation of mouse neural
progenitors. It has also been demonstrated that endothelial cells can promote
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proliferation of neural progenitors, along with differentiation down neuronal and glial
pathways [231]. Our work suggests that perhaps the endogenous endothelial cells
involved in the robust vascularization around the lesion site influenced the implanted
neural progenitors. The possibility of implanted progenitors being incorporated into
newly formed blood vessels may have benefit in the recovery after brain injury. In
particular, areas near the edge of an ischemic region, such as the penumbra in stroke
pathology, are at risk of losing viability in the absence of reperfusion. If delivery of
neural progenitors can accelerate or enhance the vascularization of these regions,
functional tissue might be spared, leading to an improved outcome. It may also be
possible to differentiate the cells into an endothelial phenotype prior to implantation. The
presence of additional endothelial cells may have a beneficial effect on both endogenous
and exogenous neural progenitors that might contribute to functional repair and recovery
through neuronal or glial differentiation.
CNPase staining allowed for visualization of myelinated axons in white matter,
but also individual oligodendrocyte cell bodies. The absence of oligodendrocytes within
the collagen scaffold is not surprising, given the large size of the lesion and the relatively
small scaffold. With a smaller injury, one might ideally expect the possibility of axons
growing through the scaffold to establish continuity across the defect, potentially
followed by myelination by oligodendrocytes. While that did not occur in this case, there
did appear to be BrdU-labeled cells that also stained positive for CNPase. As in the other
cases, cell fusion cannot be ruled out as reason for the double-labeling. However, the
multipotency of the neural progenitors has been demonstrated both in vitro and in vivo,
including the capability of oligodendrocyte differentatiation. The oligodendrocytes that
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did double-label appeared in some cases to be satellite cells located near neurons. The
functions of the permieuronal satellite oligodendrocyte remain incompletely understood,
though certain aspects of their role have been clarified. Under normal circumstances,
they are not thought to be involved in myelination. While they can be involved in
remyelinating growing axons following injury, their main role appears to be related to
metabolic support of neurons. They have been shown to localize more often with
glutamatergic cortical neurons, but can also localize with GABAergic interneurons [232].
Perineuronal oligodendrocytes express glial enzymes associated with neuronal survival
and have been suggested to protect against neuronal apoptosis, but do not appear to be
heavily involved in regulation of extracellular glutamate [233]. Neural progenitors with
the capability to differentiate into perineuronal oligodendrocytes, may be promising
candidates for neuroprotection following injury. Establishing such an effect is difficult in
this work due to the size of the lesion, but it is nonetheless likely that the differentiated
progenitors have a beneficial effect on neurons to which they have localized. In the event
that those neurons may have suffered injury or axonal damage, the perineuronal
oligodendrocytes may also be an aid in remyelination.
Most of the double-labeled oligodendrocytes seemed to be of a myelinating
phenotype. They were found in or near white matter tracts, and were sometimes found in
clusters. These cells could clearly be of benefit in replacing oligodendrocytes lost during
injury, and might also be involved in myelination of damaged or regenerating axons. The
ability of the implanted progenitors to take on oligodendrocyte phenotypes with varying
function suggests their potential utility for further application to brain injuries.
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The distribution of NeuN-positive cells confirmed that while neurons were
present in areas surrounding the lesion, no neurons were present within the scaffold.
Within areas of viable brain tissue, only an occasional neuron double-labeled with BrdU
could be identified. While the number of such cells was very few, it does appear that the
neural progenitors have the capability of developing into mature neurons after
implantation. In larger numbers, the presence of such neurons might be able to replace
certain populations of GABAergic neurons lost after injury. It has been demonstrated
that neural progenitors from the subventricular zone can migrate to sites of striatal injury
and differentiate into medium spiny neurons. It has not been definitively determined that
hippocampal progenitors have the same differentiation potential, but they have been
shown in vitro to express markers for various neuronal phenotypes. Additional staining
with a marker such as DARPP-32 might enable one to determine whether any implanted
cells might have differentiated into medium spiny neurons in the striatum. A longer term
study might also result in more neuronal differentiation.
While we have observed implanted progenitors that differentiated into astrocytes,
oligodendrocytes, neurons, endothelial cells, and possibly macrophages, there appeared
to be many BrdU positive cells that remained undifferentiated. Similar findings have
been reported in various studies of cell implantation into brain and spinal cord injury. It
has been suggested that undifferentiated cells persisting long-term in the brain may play
anti-inflammatory roles. Being able to perform labeling with 3, 4, or 5 fluorophores
simultaneously would enable a more precise determination of the proportion of
differentiated and undifferentiated cells.
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Chapter 6: Conclusions and Future Work
This thesis investigated the use of a collagen biomaterial scaffold for treatment of
penetrating brain injury in a rat model. Characterization of the injury revealed a 29%
increase in the lesion volume between 1 week and 5 weeks post-injury.
Immunohistochemistry showed a pattern of glial scarring surrounding the lesion that
consisted of reactive astrocytes and chondroitin sulfate proteoglycans.
Collagen scaffolds implanted immediately after injury showed modest cellular
infiltration after 1 week. Macrophages were the most numerous cell type, followed by
astrocytes and a small number of endothelial cells. Scaffolds implanted 1 week post-
injury (3 mm diameter) showed similar results after 4 weeks in vivo. However, the
scaffolds were small relative to the cavity size, which limited the potential interaction
with the surrounding brain.
Larger scaffolds (6 mm diameter) implanted 1 week post-injury were found to fill
most of the PBI cavity. Macrophages, astrocytes, and endothelial cells were present
within the scaffolds. In a few areas, neurons, axons, and oligodendrocytes could be
detected slightly within the scaffold margins. The lack of these cells at significant
distances within the scaffold indicate that a regenerative response did not take place.
Rather, the results showed that the scaffold can integrate with surrounding viable brain in
some areas and that neurons and oligodendrocytes can reside along the scaffold struts.
When soluble Nogo receptor was loaded into the scaffold prior to implantation, a
significant increase in macrophage and endothelial cell infiltration was noted after 4
weeks in vivo. Deposition of extracellular matrix was noted within the scaffold pores in
some cases, and there was a variable degree of vascularization with the scaffolds. In
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some cases, there were small vessels distributed throughout a large area within the
scaffold. This result suggested a promising step in modulating the lesion environment to
promote regeneration. In particular, a lesion which would otherwise be a fluid-filled
space, was thoroughly filled with a continuous extracellular matrix analog that was
vascularized and supportive of cellular infiltration. Future work may be aimed at
designing a scaffold that can be resorbed over time to limit the macrophage and giant cell
response while remaining in vivo long enough to promote vascularization. Additionally,
one may attempt to deliver a cellular or pharmacological therapy to the vascularized
lesion site to promote a regenerative response.
Implantation of a collagen scaffold seeded with neural progenitor cells was
resulted in the survival and differentiation of numerous cells into a variety of phenotypes.
Differentiation into astrocytes, oligodendrocytes, endothelial cells, neurons, and
potentially macrophages was observed. Future work might focus on implanting a similar
construct into a smaller lesion, such that the cavity is better filled by the scaffold. This
would allow for increased interaction of the implanted cells with the surrounding brain
tissue. Additionally, potential positive effects of the cells are more likely to be detected
when the lesion is not overwhelmingly large.
With the information gained from this work, another logical next step would be to
combine the therapies we have investigated. This could be done in a sequential manner
by beginning with implantation of a sNgR loaded scaffold following the injury. After
allowing several weeks for vascularization, one might then inject a population of neural
progenitors into the lesion site. It is hypothesized that the cells would show an increased
190
survival rate relative to implantation of a cell-seeded scaffold into the unvascularized
lesion.
This research has demonstrated the complexity of trying to develop therapeutic
options for CNS injuries. The knowledge gained will hopefully contribute to further
work in the area and eventually treatment options for affected patients.
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